The Glucose Never Lies® Podcast Wed, 08 Jul 2026 17:28:47 -0400 http://www.theglucoseneverlies.com en-gb © 2026 The Glucose Never Lies® Podcast yes ff78430d-c89a-5d09-a7f4-a3c67b0d7cbe John Pemberton episodic false Host John Pemberton — diabetes educator, researcher, and dad living with type 1 since 2008 — explores how to think clearly about type 1 diabetes in the real world.


Each episode translates current evidence and expert practice into decisions you can use: CGM accuracy and interpretation, getting more from pumps and automated insulin delivery, movement as a glucose tool, nutrition that protects performance and enjoyment, sleep, travel, parties, and sport.


Guests include leading clinicians, researchers, and people with lived experience. Expect respectful challenge, plain language, and practical take-aways.


Note: Educational only. No therapeutic relationship or personal medical advice.


Buy the GNL a Coffee to keep us independent:  https://www.buymeacoffee.com/jspfree2s


Email: john@theglucoseneverlies.com 

]]> Buzzsprout (https://www.buzzsprout.com) Type 1 diabetes, Health, Continuous Glucose Monitoring, Automated Insulin Delivery, Exercise, Nutrition, Research, Lived Experience, Dynamic Glucose Management John Pemberton https://storage.buzzsprout.com/4ocx5dacjk7br9tob913f1nlqmtg?.jpg The Glucose Never Lies® Podcast http://www.theglucoseneverlies.com John Pemberton Episode 42: DICE 2026 - The Highlights Episode 42: DICE 2026 - The Highlights Suggest guests or get in contact

Suggest guests or get in contact

John Pemberton was at Croke Park on 21 May for DICE — Diabetes Ireland Conference and Exhibition — Ireland's premier annual event for healthcare professionals working in diabetes. The day also saw the launch of the landmark National Policy and Services Review for diabetes in Ireland. John grabbed a microphone and seven conversations. This episode is all of them.

Anjanee Kohli is Co-Director and Creative Director of The Glucose Never Lies® and the host for this episode. John Pemberton is founder of The Glucose Never Lies® and a paediatric diabetes dietitian at Birmingham Women's and Children's NHS Foundation Trust; he is also a person living with T1D. This episode reflects the independent views of both.

This episode covers:

  • Sinead Powell (Education and Support Coordinator, Diabetes Ireland): the COPE programme, emotional wellbeing in type 2 diabetes, language, stigma, and why information alone is never enough
  • Kathy Breen (Clinical Specialist Dietitian and Dietetic Lead, National Diabetes Programme): what Language Matters looks like in practice, person-first language, and its inclusion in the new national strategy
  • Kate Gaievska (Clinical Manager for Advocacy and Research, Diabetes Ireland): why adult diabetes psychology services in Ireland are effectively non-existent, what the strategy commits to, and the long road of implementation
  • Professor Fidelma Dunne (University of Galway / National Clinical Trials Network in Diabetes): how clinical trials get funded, why real-world data matters, and why research is not the icing on the cake
  • Christine Newman (Diabetes Consultant, Galway): hybrid closed-loop in pregnancy, CGM for type 2, and the case for free glucose strips for gestational diabetes
  • Professor Derek O'Keefe (Consultant Physician and Professor of Medical Device Technology, UHG): Mochara, a bounded AI education tool that matched nurse and doctor performance in trials, ambient clinical documentation, intelligent dynamic triage, and what multimodal AI means for diabetes care
  • Dr Tomas Griffin (Consultant Diabetologist, Galway / DTN Ireland): what the strategy means for pump access, the DTN Ireland roadshow, and why every tier of hospital in Ireland is now starting pump therapy

Show notes: https://theglucoseneverlies.com/

Have more questions? Ask GNL Grace, a diabetes educational adviser built by a team with skin in the game. Grace gets you 80% of the way there with 20% of the effort; the final 20% takes self-discovery, guided by human expertise and trial-and-error learning. https://theglucoseneverlies.com/gnl-grace/

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Suggest guests or get in contact

John Pemberton was at Croke Park on 21 May for DICE — Diabetes Ireland Conference and Exhibition — Ireland's premier annual event for healthcare professionals working in diabetes. The day also saw the launch of the landmark National Policy and Services Review for diabetes in Ireland. John grabbed a microphone and seven conversations. This episode is all of them.

Anjanee Kohli is Co-Director and Creative Director of The Glucose Never Lies® and the host for this episode. John Pemberton is founder of The Glucose Never Lies® and a paediatric diabetes dietitian at Birmingham Women's and Children's NHS Foundation Trust; he is also a person living with T1D. This episode reflects the independent views of both.

This episode covers:

  • Sinead Powell (Education and Support Coordinator, Diabetes Ireland): the COPE programme, emotional wellbeing in type 2 diabetes, language, stigma, and why information alone is never enough
  • Kathy Breen (Clinical Specialist Dietitian and Dietetic Lead, National Diabetes Programme): what Language Matters looks like in practice, person-first language, and its inclusion in the new national strategy
  • Kate Gaievska (Clinical Manager for Advocacy and Research, Diabetes Ireland): why adult diabetes psychology services in Ireland are effectively non-existent, what the strategy commits to, and the long road of implementation
  • Professor Fidelma Dunne (University of Galway / National Clinical Trials Network in Diabetes): how clinical trials get funded, why real-world data matters, and why research is not the icing on the cake
  • Christine Newman (Diabetes Consultant, Galway): hybrid closed-loop in pregnancy, CGM for type 2, and the case for free glucose strips for gestational diabetes
  • Professor Derek O'Keefe (Consultant Physician and Professor of Medical Device Technology, UHG): Mochara, a bounded AI education tool that matched nurse and doctor performance in trials, ambient clinical documentation, intelligent dynamic triage, and what multimodal AI means for diabetes care
  • Dr Tomas Griffin (Consultant Diabetologist, Galway / DTN Ireland): what the strategy means for pump access, the DTN Ireland roadshow, and why every tier of hospital in Ireland is now starting pump therapy

Show notes: https://theglucoseneverlies.com/

Have more questions? Ask GNL Grace, a diabetes educational adviser built by a team with skin in the game. Grace gets you 80% of the way there with 20% of the effort; the final 20% takes self-discovery, guided by human expertise and trial-and-error learning. https://theglucoseneverlies.com/gnl-grace/

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-19268136 Mon, 01 Jun 2026 08:00:00 +0100 4187 42 full false Ep 41: CGM Series Round-Up, Grace Update and John on Diabetech Ep 41: CGM Series Round-Up, Grace Update and John on Diabetech Suggest guests or get in contact

Every few months, The Glucose Never Lies stops and takes stock. No single guest, no single topic: three CGM Series episodes have landed since the last round-up, Grace has a new model, and John has appeared on two podcasts that are not his own. This episode covers all of it.

Anjanee Kohli is Co-Director and Creative Director of The Glucose Never Lies® and the host for this episode. John Pemberton is founder of The Glucose Never Lies® and a paediatric diabetes dietitian at Birmingham Women's and Children's NHS Foundation Trust; he is also a person living with T1D. This episode reflects the independent views of both.

This episode covers:
- CGM Series catch-up: episodes 38, 39, and 40 in one conversation
- The IFCC glucose stress test: what it measures, the CE-versus-FDA accuracy gap, and the car crash analogy for insulin-dosing sensors
- The MDI generation gap: why people on injections have had one generation of CGM while pump users have had five
- What 17 early adopters actually reported about Night Low Predict and Glucose Predict on the Accu-Chek SmartGuide
- Grace's new model: a 30-day free trial for everyone, then Personal at £5 a month (£50 a year) and HCP at £20 a month (£200 a year); a £5 Buy Me a Coffee sponsorship opens a free account for someone on the waiting list
- The near-bankruptcy moment: flat architecture to wiki retrieval layer, cost reduced to roughly five per cent
- Why Grace has no memory by design: the deliberate reasoning behind a deliberate constraint
- John on Diabetech (Gary Shiner's show, hosted by Justin): CGM international testing standards
- John on Tomorrow's Medicine with Arseniy Arsentyev: how Grace was built, the antibody result that started it, and what nearly ended it
- AI and healthcare work: the people who adapt, the people who hide behind procedure, and what cannot be automated

Show notes: https://theglucoseneverlies.com/episode-41-cgm-series-grace-diabetech/

Before this episode, John appeared on:
Diabetech (Gary Shiner's show, hosted by Justin): https://youtu.be/6sxM1HOxcP4?si=2B3lHzyjSBgPKYfb
Tomorrow's Medicine with Arseniy Arsentyev: https://youtu.be/60MZGAk86NY?si=l3oF1J37EiI7fcCE

Have more questions? Ask GNL Grace, a diabetes educational advisor built by a team with skin in the game. Grace gets you 80% of the way there with 20% of the effort; the final 20% takes self-discovery, guided by human expertise and trial-and-error learning. https://theglucoseneverlies.com/gnl-grace/

---

Disclaimer
This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design
We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee: https://www.buymeacoffee.com/gnlfree

Enquiries
Collaboration: John Pemberton, john@theglucoseneverlies.com
Creatives: Anjanee Kohli, anj@theglucoseneverlies.com

Follow The Glucose Never Lies®
Website: https://theglucoseneverlies.com/
Instagram: https://www.instagram.com/theglucoseneverlies
LinkedIn: https://www.linkedin.com/company/theglucoseneverlies
LinkedIn John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/
LinkedIn Anjanee Kohli: https://www.linkedin.com/in/anjanee-kohli-chohan-1b22a217b/
Instagram Anjanee Kohli: https://www.instagram.com/anjanee.dietitian
X: https://twitter.com/GlucoseNLies

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Every few months, The Glucose Never Lies stops and takes stock. No single guest, no single topic: three CGM Series episodes have landed since the last round-up, Grace has a new model, and John has appeared on two podcasts that are not his own. This episode covers all of it.

Anjanee Kohli is Co-Director and Creative Director of The Glucose Never Lies® and the host for this episode. John Pemberton is founder of The Glucose Never Lies® and a paediatric diabetes dietitian at Birmingham Women's and Children's NHS Foundation Trust; he is also a person living with T1D. This episode reflects the independent views of both.

This episode covers:
- CGM Series catch-up: episodes 38, 39, and 40 in one conversation
- The IFCC glucose stress test: what it measures, the CE-versus-FDA accuracy gap, and the car crash analogy for insulin-dosing sensors
- The MDI generation gap: why people on injections have had one generation of CGM while pump users have had five
- What 17 early adopters actually reported about Night Low Predict and Glucose Predict on the Accu-Chek SmartGuide
- Grace's new model: a 30-day free trial for everyone, then Personal at £5 a month (£50 a year) and HCP at £20 a month (£200 a year); a £5 Buy Me a Coffee sponsorship opens a free account for someone on the waiting list
- The near-bankruptcy moment: flat architecture to wiki retrieval layer, cost reduced to roughly five per cent
- Why Grace has no memory by design: the deliberate reasoning behind a deliberate constraint
- John on Diabetech (Gary Shiner's show, hosted by Justin): CGM international testing standards
- John on Tomorrow's Medicine with Arseniy Arsentyev: how Grace was built, the antibody result that started it, and what nearly ended it
- AI and healthcare work: the people who adapt, the people who hide behind procedure, and what cannot be automated

Show notes: https://theglucoseneverlies.com/episode-41-cgm-series-grace-diabetech/

Before this episode, John appeared on:
Diabetech (Gary Shiner's show, hosted by Justin): https://youtu.be/6sxM1HOxcP4?si=2B3lHzyjSBgPKYfb
Tomorrow's Medicine with Arseniy Arsentyev: https://youtu.be/60MZGAk86NY?si=l3oF1J37EiI7fcCE

Have more questions? Ask GNL Grace, a diabetes educational advisor built by a team with skin in the game. Grace gets you 80% of the way there with 20% of the effort; the final 20% takes self-discovery, guided by human expertise and trial-and-error learning. https://theglucoseneverlies.com/gnl-grace/

---

Disclaimer
This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design
We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee: https://www.buymeacoffee.com/gnlfree

Enquiries
Collaboration: John Pemberton, john@theglucoseneverlies.com
Creatives: Anjanee Kohli, anj@theglucoseneverlies.com

Follow The Glucose Never Lies®
Website: https://theglucoseneverlies.com/
Instagram: https://www.instagram.com/theglucoseneverlies
LinkedIn: https://www.linkedin.com/company/theglucoseneverlies
LinkedIn John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/
LinkedIn Anjanee Kohli: https://www.linkedin.com/in/anjanee-kohli-chohan-1b22a217b/
Instagram Anjanee Kohli: https://www.instagram.com/anjanee.dietitian
X: https://twitter.com/GlucoseNLies

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-19184933 Mon, 18 May 2026 08:00:00 +0100 2412 T1D, CGM, FreeStyle Libre, Accu-Chek, Grace, Diabetech, diabetes education 41 full false Episode 40 - Accu-Chek SmartGuide: CGM Generation 2.0 for MDI | Amy Jolley | GNL Podcast Episode 40 - Accu-Chek SmartGuide: CGM Generation 2.0 for MDI | Amy Jolley | GNL Podcast Suggest guests or get in contact

People on MDI have had one generation of CGM technology: a sensor that tells you what your glucose is doing now, with a 15-minute trend arrow. While pump users have moved through five iterations, injection users have been waiting. The Accu-Chek SmartGuide is the first attempt at a second generation - and this episode asks whether it delivers.

Amy Jolley is a Highly Specialised Dietitian, Lead Educator at the Diabetes Technology Network UK, and Lead for the Young Adult and Transition Service at Salford NHS Foundation Trust. This episode is not endorsed by Roche Diagnostics, but the experience of a healthcare professional's experience of putting 17 people onto the SmartGuide in one week, running group onboarding sessions, and asking them to come back and tell her what actually happened. Her host, John Pemberton, is founder of The Glucose Never Lies® and a person living with T1D. 

This episode covers:
- Why MDI has been stuck at Generation 1 while pump technology moved through five iterations
- Night Low Predict: RAG ratings, first-half versus second-half of the night, and how to teach it
- Glucose Predict: the 45-minute action window versus the two-hour awareness window
- What 17 early adopters actually reported back
- How the 45-minute look ahead reduces the rage bolus
- Why calibration is an educational opportunity, not a drawback
- CGM market saturation and the DTN quality standard
- The DTN Competency Assessment Framework: four tiers, self-assessment, a training passport for clinicians
- GNL Grace in clinical practice: Amy's feedback from a specialist service supporting 700 AID users

Show notes: https://theglucoseneverlies.com/accu-chek-smartguide-mdi-cgm-series/

Have more questions? Ask GNL Grace, a diabetes educational advisor built by a team with skin in the game. Grace gets you 80% of the way there with 20% of the effort; the final 20% takes self-discovery, guided by human expertise and trial-and-error learning. https://theglucoseneverlies.com/gnl-grace/

---

Disclaimer
This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design
We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee: https://www.buymeacoffee.com/gnlfree

Enquiries
Collaboration: John Pemberton, john@theglucoseneverlies.com
Creatives: Anjanee Kohli, anj@theglucoseneverlies.com

Follow The Glucose Never Lies®
Website: https://theglucoseneverlies.com/
Instagram: https://www.instagram.com/theglucoseneverlies
LinkedIn: https://www.linkedin.com/company/theglucoseneverlies
LinkedIn John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/
LinkedIn Anjanee Kohli: https://www.linkedin.com/in/anjanee-kohli-chohan-1b22a217b/
Instagram Anjanee Kohli: https://www.instagram.com/anjanee.dietitian
X: https://twitter.com/GlucoseNLies

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

People on MDI have had one generation of CGM technology: a sensor that tells you what your glucose is doing now, with a 15-minute trend arrow. While pump users have moved through five iterations, injection users have been waiting. The Accu-Chek SmartGuide is the first attempt at a second generation - and this episode asks whether it delivers.

Amy Jolley is a Highly Specialised Dietitian, Lead Educator at the Diabetes Technology Network UK, and Lead for the Young Adult and Transition Service at Salford NHS Foundation Trust. This episode is not endorsed by Roche Diagnostics, but the experience of a healthcare professional's experience of putting 17 people onto the SmartGuide in one week, running group onboarding sessions, and asking them to come back and tell her what actually happened. Her host, John Pemberton, is founder of The Glucose Never Lies® and a person living with T1D. 

This episode covers:
- Why MDI has been stuck at Generation 1 while pump technology moved through five iterations
- Night Low Predict: RAG ratings, first-half versus second-half of the night, and how to teach it
- Glucose Predict: the 45-minute action window versus the two-hour awareness window
- What 17 early adopters actually reported back
- How the 45-minute look ahead reduces the rage bolus
- Why calibration is an educational opportunity, not a drawback
- CGM market saturation and the DTN quality standard
- The DTN Competency Assessment Framework: four tiers, self-assessment, a training passport for clinicians
- GNL Grace in clinical practice: Amy's feedback from a specialist service supporting 700 AID users

Show notes: https://theglucoseneverlies.com/accu-chek-smartguide-mdi-cgm-series/

Have more questions? Ask GNL Grace, a diabetes educational advisor built by a team with skin in the game. Grace gets you 80% of the way there with 20% of the effort; the final 20% takes self-discovery, guided by human expertise and trial-and-error learning. https://theglucoseneverlies.com/gnl-grace/

---

Disclaimer
This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design
We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee: https://www.buymeacoffee.com/gnlfree

Enquiries
Collaboration: John Pemberton, john@theglucoseneverlies.com
Creatives: Anjanee Kohli, anj@theglucoseneverlies.com

Follow The Glucose Never Lies®
Website: https://theglucoseneverlies.com/
Instagram: https://www.instagram.com/theglucoseneverlies
LinkedIn: https://www.linkedin.com/company/theglucoseneverlies
LinkedIn John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/
LinkedIn Anjanee Kohli: https://www.linkedin.com/in/anjanee-kohli-chohan-1b22a217b/
Instagram Anjanee Kohli: https://www.instagram.com/anjanee.dietitian
X: https://twitter.com/GlucoseNLies

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-19146425 Mon, 11 May 2026 08:00:00 +0100 3460 40 full false Episode 39: Abbott FreeStyle Libre - Accuracy, Simplicity and What's Next Episode 39: Abbott FreeStyle Libre - Accuracy, Simplicity and What's Next Suggest guests or get in contact

Michael Skarlatos from Abbott UK Medical Affairs joins John Pemberton for the second manufacturer episode of the CGM Series. A former diabetes specialist dietitian at University Hospitals of Leicester, Michael brings real clinical experience to an honest breakdown of the FreeStyle Libre 2 Plus and 3 Plus.

This episode covers:
- Why Abbott accuracy data qualifies these sensors for insulin dosing: ICGM approved, 20/20 performance ~95-96%, outside-40/40 error rate 0.2%
- What 70% smaller means in practice: form factor, stigma, and the all-in-one applicator on Libre 3 Plus
- Pump integrations now and the roadmap: CamAPS FX, Omnipod 5, and what is coming
- Libreview: why Abbott moved off Glooko and what population health management enables
- Libreview Pro in SystmOne and EMIS with SNOMED-coded CGM metrics
- A critical data nuance: glucose measured every minute on the patient app but recorded every 5 minutes in clinical downloads
- Continuous ketone monitoring: what Abbott has in development and who benefits most

CHAPTERS
00:00 Introduction and CGM Series overview
00:57 Michaels background and Leicester NHS Trust
02:25 Moving from NHS to Abbott Medical Affairs
03:27 Accuracy credentials: ICGM approval and 20/20 performance
05:44 FreeStyle Libre 3 Plus: size and form factor
09:25 Pump integrations: CamAPS FX, Omnipod 5, and the roadmap
10:19 ICGM interoperability: US vs CE marking in Europe
12:05 Fifteen-day wear period
12:28 Abbott market history: free samples and patient-led adoption
14:04 Simplicity of onboarding and multi-language support
16:58 Starter clinics: taking onboarding off the HCP
19:33 Libreview and population health management
23:21 EHR integration, SNOMED codes, and QOF implications
25:46 Practical tips: Bluetooth connectivity and the app cache
29:23 Minute-by-minute data vs five-minute trend recording
30:58 Low glucose event thresholds and hypo underreporting
31:42 Continuous ketone monitoring: what is coming from Abbott
37:52 CGM beyond type 1 and patient advocacy
40:17 Closing thoughts

LINKS
Show notes: https://theglucoseneverlies.com/episode-38-freestyle-libre-abbott/
YouTube: https://youtu.be/IW1sa5APHU8
CGM Series: https://theglucoseneverlies.com/10-13-cgm-series/
GNL Explorers: https://theglucoseneverlies.com/gnl-grace/

Buzzsprout: https://www.buzzsprout.com/2451357/18982022
Apple Podcasts: https://podcasts.apple.com/gb/podcast/the-glucose-never-lies/id1795741144
Spotify: https://open.spotify.com/show/2MlGlz2G8LsbDnuGtAh77W

This content is for educational exploration only. Not medical advice.

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Michael Skarlatos from Abbott UK Medical Affairs joins John Pemberton for the second manufacturer episode of the CGM Series. A former diabetes specialist dietitian at University Hospitals of Leicester, Michael brings real clinical experience to an honest breakdown of the FreeStyle Libre 2 Plus and 3 Plus.

This episode covers:
- Why Abbott accuracy data qualifies these sensors for insulin dosing: ICGM approved, 20/20 performance ~95-96%, outside-40/40 error rate 0.2%
- What 70% smaller means in practice: form factor, stigma, and the all-in-one applicator on Libre 3 Plus
- Pump integrations now and the roadmap: CamAPS FX, Omnipod 5, and what is coming
- Libreview: why Abbott moved off Glooko and what population health management enables
- Libreview Pro in SystmOne and EMIS with SNOMED-coded CGM metrics
- A critical data nuance: glucose measured every minute on the patient app but recorded every 5 minutes in clinical downloads
- Continuous ketone monitoring: what Abbott has in development and who benefits most

CHAPTERS
00:00 Introduction and CGM Series overview
00:57 Michaels background and Leicester NHS Trust
02:25 Moving from NHS to Abbott Medical Affairs
03:27 Accuracy credentials: ICGM approval and 20/20 performance
05:44 FreeStyle Libre 3 Plus: size and form factor
09:25 Pump integrations: CamAPS FX, Omnipod 5, and the roadmap
10:19 ICGM interoperability: US vs CE marking in Europe
12:05 Fifteen-day wear period
12:28 Abbott market history: free samples and patient-led adoption
14:04 Simplicity of onboarding and multi-language support
16:58 Starter clinics: taking onboarding off the HCP
19:33 Libreview and population health management
23:21 EHR integration, SNOMED codes, and QOF implications
25:46 Practical tips: Bluetooth connectivity and the app cache
29:23 Minute-by-minute data vs five-minute trend recording
30:58 Low glucose event thresholds and hypo underreporting
31:42 Continuous ketone monitoring: what is coming from Abbott
37:52 CGM beyond type 1 and patient advocacy
40:17 Closing thoughts

LINKS
Show notes: https://theglucoseneverlies.com/episode-38-freestyle-libre-abbott/
YouTube: https://youtu.be/IW1sa5APHU8
CGM Series: https://theglucoseneverlies.com/10-13-cgm-series/
GNL Explorers: https://theglucoseneverlies.com/gnl-grace/

Buzzsprout: https://www.buzzsprout.com/2451357/18982022
Apple Podcasts: https://podcasts.apple.com/gb/podcast/the-glucose-never-lies/id1795741144
Spotify: https://open.spotify.com/show/2MlGlz2G8LsbDnuGtAh77W

This content is for educational exploration only. Not medical advice.

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18982022 Mon, 27 Apr 2026 08:00:00 +0100 2494 39 full false Episode 38: Q1 2026 Quarterly Review, GNL Grace, the Explorers, and What Changed Episode 38: Q1 2026 Quarterly Review, GNL Grace, the Explorers, and What Changed Suggest guests or get in contact

Three months ago, GNL was a website full of excellent content that was genuinely hard to find. In Episode 38, John Pemberton and Creative Director Anjanee Kohli talk through what happened next: a complete website rebuild, five interactive explorers, the launch of GNL Grace, and the evidence base behind it, drawn from approximately 500,000 patient-days across roughly 1,300 people living with diabetes over more than 10 years.

In this episode:

  • CGM guide update and the five-out-of-five accuracy chart
  • How the five GNL Explorers work and how clinicians are using them in practice
  • GNL Grace: a bounded AI educational advisor built on 2,000 curated citations
  • Grace: a 30-day free trial for everyone, then Personal at £5 a month and HCP at £20 a month
  • Real-world validation: approximately 500,000 patient-days across roughly 1,300 people living with diabetes over more than 10 years
  • Why the skill of the future in healthcare is compassion, not knowledge
  • Phil Hayes joining as Technical Director
  • GNL merch and the Diabetes UK giveaway

Chapters:

  • 00:00 Introduction
  • 01:55 GNL Grace announcement
  • 02:32 CGM guide and accuracy chart
  • 05:30 Phil Hayes and the explorer infrastructure
  • 09:40 GNL Grace: the six-layer bounded AI
  • 10:50 Grace tiers explained
  • 13:31 Grace Max: manuscript-grade output
  • 17:31 Real-world validation: the evidence base behind Grace
  • 19:58 The skill of the future is compassion
  • 30:09 What went wrong and lessons learned
  • 35:06 GNL merch
  • 36:10 Closing

Links:

Host: John Pemberton. Director of Creativity: Anjanee Kohli.

This content is for educational exploration only. It is not medical advice and cannot replace individual clinical guidance from your diabetes care team.

Support GNL: https://www.buymeacoffee.com/gnlfree

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Three months ago, GNL was a website full of excellent content that was genuinely hard to find. In Episode 38, John Pemberton and Creative Director Anjanee Kohli talk through what happened next: a complete website rebuild, five interactive explorers, the launch of GNL Grace, and the evidence base behind it, drawn from approximately 500,000 patient-days across roughly 1,300 people living with diabetes over more than 10 years.

In this episode:

  • CGM guide update and the five-out-of-five accuracy chart
  • How the five GNL Explorers work and how clinicians are using them in practice
  • GNL Grace: a bounded AI educational advisor built on 2,000 curated citations
  • Grace: a 30-day free trial for everyone, then Personal at £5 a month and HCP at £20 a month
  • Real-world validation: approximately 500,000 patient-days across roughly 1,300 people living with diabetes over more than 10 years
  • Why the skill of the future in healthcare is compassion, not knowledge
  • Phil Hayes joining as Technical Director
  • GNL merch and the Diabetes UK giveaway

Chapters:

  • 00:00 Introduction
  • 01:55 GNL Grace announcement
  • 02:32 CGM guide and accuracy chart
  • 05:30 Phil Hayes and the explorer infrastructure
  • 09:40 GNL Grace: the six-layer bounded AI
  • 10:50 Grace tiers explained
  • 13:31 Grace Max: manuscript-grade output
  • 17:31 Real-world validation: the evidence base behind Grace
  • 19:58 The skill of the future is compassion
  • 30:09 What went wrong and lessons learned
  • 35:06 GNL merch
  • 36:10 Closing

Links:

Host: John Pemberton. Director of Creativity: Anjanee Kohli.

This content is for educational exploration only. It is not medical advice and cannot replace individual clinical guidance from your diabetes care team.

Support GNL: https://www.buymeacoffee.com/gnlfree

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-19040509 Mon, 20 Apr 2026 08:00:00 +0100 2199 38 full false Episode 37: Dexcom G7 and ONE+| Adam Dawes | GNL Podcast Episode 37: Dexcom G7 and ONE+| Adam Dawes | GNL Podcast Suggest guests or get in contact

Most people with T1D have switched their CGM high alert off. Not because they do not care - because it goes off every time they eat and there is nothing they can do about it. Episode 37 is about what Dexcom built to fix that.

Adam Dawes, Senior Medical Affairs Manager at Dexcom UK and Ireland - and a former paediatric diabetes nurse specialist - joins John Pemberton for the third manufacturer episode of the CGM Series. An honest clinical conversation about the Dexcom G7 and ONE+, what separates them, and where Dexcom is heading next.

This episode covers:
- Dexcom G7 vs Dexcom ONE+: same hardware platform, different software, and what that means for matching the right sensor to the right patient
- Delay 1st Alert: why it is one of the most underused alerts in CGM, how it eliminates alarm fatigue without reducing safety, and how John uses it himself
- AID integrations: Tandem T:slim X2, Omnipod 5, mylife, and the Tandem Mobi
- CGM for type 2 diabetes: the biofeedback argument and why immediate glucose feedback changes behaviour in ways a quarterly HbA1c never can
- The Dexcom roadmap from ATTD 2026: 15-day sensor, Dexcom G8 next generation sensor, EPIC integration, Clarity updates, and generative AI
- Why insulin dosing will never be a commodity market - and what people with T1D need to understand as new CGMs enter the UK
- The FDA manufacturing findings: what happened, how Dexcom responded, and why the new Ireland factory matters

Show notes: https://theglucoseneverlies.com/episode-37-dexcom-g7-one-plus/ | CGM Series: https://theglucoseneverlies.com/10-13-cgm-series/

Have more questions about CGM, the Dexcom G7 or ONE+? Ask GNL Grace: https://theglucoseneverlies.com/gnl-grace/

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Most people with T1D have switched their CGM high alert off. Not because they do not care - because it goes off every time they eat and there is nothing they can do about it. Episode 37 is about what Dexcom built to fix that.

Adam Dawes, Senior Medical Affairs Manager at Dexcom UK and Ireland - and a former paediatric diabetes nurse specialist - joins John Pemberton for the third manufacturer episode of the CGM Series. An honest clinical conversation about the Dexcom G7 and ONE+, what separates them, and where Dexcom is heading next.

This episode covers:
- Dexcom G7 vs Dexcom ONE+: same hardware platform, different software, and what that means for matching the right sensor to the right patient
- Delay 1st Alert: why it is one of the most underused alerts in CGM, how it eliminates alarm fatigue without reducing safety, and how John uses it himself
- AID integrations: Tandem T:slim X2, Omnipod 5, mylife, and the Tandem Mobi
- CGM for type 2 diabetes: the biofeedback argument and why immediate glucose feedback changes behaviour in ways a quarterly HbA1c never can
- The Dexcom roadmap from ATTD 2026: 15-day sensor, Dexcom G8 next generation sensor, EPIC integration, Clarity updates, and generative AI
- Why insulin dosing will never be a commodity market - and what people with T1D need to understand as new CGMs enter the UK
- The FDA manufacturing findings: what happened, how Dexcom responded, and why the new Ireland factory matters

Show notes: https://theglucoseneverlies.com/episode-37-dexcom-g7-one-plus/ | CGM Series: https://theglucoseneverlies.com/10-13-cgm-series/

Have more questions about CGM, the Dexcom G7 or ONE+? Ask GNL Grace: https://theglucoseneverlies.com/gnl-grace/

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18949948 Mon, 13 Apr 2026 09:00:00 +0100 3222 37 full false 36: CGM Series - CGM Accuracy, DSN Reality Checks and the Future of Diabetes Technology 36: CGM Series - CGM Accuracy, DSN Reality Checks and the Future of Diabetes Technology Suggest guests or get in contact

CGM Series | The Glucose Never Lies® Podcast

Three of the UK's leading diabetes specialist nurses on why CE marking is not a quality standard for CGM accuracy, why data sufficiency must come before device comparison, and what ATTD 2025 revealed about where diabetes technology is heading. A frank, clinical conversation grounded in years of front-line practice — and the story of how the DSN Forum's five-point accuracy scoring system was built.

In this episode:

  • Why the DSN Forum created its CGM comparison chart and how it has evolved
  • Why CE marking is not a quality standard for CGM accuracy
  • How the five-point accuracy scoring system works and what it requires from a device
  • Why only four devices currently meet the data sufficiency standard
  • What 20/20 and 40/40 agreement rates mean in real clinical terms
  • Why everyone using CGM for insulin decisions still needs a working finger-prick meter
  • The calibration debate: does the option to calibrate add safety or risk?
  • What ATTD 2025 revealed about fully closed loop systems — and who may not benefit
  • The case for GLP-1 in type 1 diabetes and why priority access matters
  • Abbott's continuous ketone monitor: opportunity, unknowns, and risks
  • AID system optimisation, insulin on board, and the GNL AID System Explorer

Chapters:

  • 00:00 — Introduction: meeting Amanda, Beth and Tamsin
  • 02:14 — Why the DSN Forum CGM comparison chart was created
  • 06:47 — Turning complex CGM evidence into a practical scoring system
  • 16:23 — How CGM choice works in real clinical settings
  • 20:36 — Why finger-prick testing still matters — and the calibration debate
  • 29:26 — What stood out at ATTD 2025
  • 44:03 — AID systems, insulin on board, and the GNL AID optimiser
  • 49:49 — Where to find the DSN Forum, the chart, and closing thoughts

Guests: Amanda Williams (Lead Diabetes Nurse, East Kent), Beth Kelly (Clinical Lead DSN, Wiltshire), Tamsin Fletcher-Salt (Lead DSN, University Hospital North Midlands). All core members of the Diabetes Specialist Nurse Forum UK.

Links:

  • Full show notes: https://theglucoseneverlies.com/episode-36-cgm-accuracy-dsn-forum/
  • DSN Forum CGM Comparison Chart: https://www.diabetesspecialistnurseforumuk.co.uk/new-cgm-comparison-chart
  • CGM Guide Part 2 — Assessing CGM Accuracy: https://theglucoseneverlies.com/assessing-cgm-accuracy-performance/
  • GNL AID System Explorer: https://theglucoseneverlies.com/aid-system-explorer/
  • Episode 35 — Professor Othmar Moser on CGM Study Design: https://theglucoseneverlies.com/episode-35-cgm-series-the-importance-of-cgm-accuracy-and-study-design-with-professor-othmar-moser/

Educational purposes only. Not medical advice. Always work with your diabetes care team.

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

CGM Series | The Glucose Never Lies® Podcast

Three of the UK's leading diabetes specialist nurses on why CE marking is not a quality standard for CGM accuracy, why data sufficiency must come before device comparison, and what ATTD 2025 revealed about where diabetes technology is heading. A frank, clinical conversation grounded in years of front-line practice — and the story of how the DSN Forum's five-point accuracy scoring system was built.

In this episode:

  • Why the DSN Forum created its CGM comparison chart and how it has evolved
  • Why CE marking is not a quality standard for CGM accuracy
  • How the five-point accuracy scoring system works and what it requires from a device
  • Why only four devices currently meet the data sufficiency standard
  • What 20/20 and 40/40 agreement rates mean in real clinical terms
  • Why everyone using CGM for insulin decisions still needs a working finger-prick meter
  • The calibration debate: does the option to calibrate add safety or risk?
  • What ATTD 2025 revealed about fully closed loop systems — and who may not benefit
  • The case for GLP-1 in type 1 diabetes and why priority access matters
  • Abbott's continuous ketone monitor: opportunity, unknowns, and risks
  • AID system optimisation, insulin on board, and the GNL AID System Explorer

Chapters:

  • 00:00 — Introduction: meeting Amanda, Beth and Tamsin
  • 02:14 — Why the DSN Forum CGM comparison chart was created
  • 06:47 — Turning complex CGM evidence into a practical scoring system
  • 16:23 — How CGM choice works in real clinical settings
  • 20:36 — Why finger-prick testing still matters — and the calibration debate
  • 29:26 — What stood out at ATTD 2025
  • 44:03 — AID systems, insulin on board, and the GNL AID optimiser
  • 49:49 — Where to find the DSN Forum, the chart, and closing thoughts

Guests: Amanda Williams (Lead Diabetes Nurse, East Kent), Beth Kelly (Clinical Lead DSN, Wiltshire), Tamsin Fletcher-Salt (Lead DSN, University Hospital North Midlands). All core members of the Diabetes Specialist Nurse Forum UK.

Links:

  • Full show notes: https://theglucoseneverlies.com/episode-36-cgm-accuracy-dsn-forum/
  • DSN Forum CGM Comparison Chart: https://www.diabetesspecialistnurseforumuk.co.uk/new-cgm-comparison-chart
  • CGM Guide Part 2 — Assessing CGM Accuracy: https://theglucoseneverlies.com/assessing-cgm-accuracy-performance/
  • GNL AID System Explorer: https://theglucoseneverlies.com/aid-system-explorer/
  • Episode 35 — Professor Othmar Moser on CGM Study Design: https://theglucoseneverlies.com/episode-35-cgm-series-the-importance-of-cgm-accuracy-and-study-design-with-professor-othmar-moser/

Educational purposes only. Not medical advice. Always work with your diabetes care team.

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18921411 Sun, 29 Mar 2026 06:00:00 +0100 3084 36 full false 35: CGM Series - The Importance of CGM Accuracy and Study Design with Professor Othmar Moser 35: CGM Series - The Importance of CGM Accuracy and Study Design with Professor Othmar Moser Suggest guests or get in contact

CGM Series | The Glucose Never Lies® Podcast

CGM accuracy is usually described with a single number: MARD. But a low MARD can hide significant risk if the study behind it was poorly designed. Professor Othmar Moser — one of the leading independent CGM accuracy researchers — explains what study design actually determines, why meal and insulin challenges are non-negotiable, and what people with type 1 diabetes and clinicians should look for when evaluating any accuracy claim.

In this episode:

  • What MARD is and why it misleads when used in isolation
  • The five study design questions that determine what accuracy data actually means
  • Why 20/20 and 40/40 agreement rates reveal what MARD cannot
  • Why meal and insulin challenges are essential for real-world accuracy testing
  • What CE marking does and does not guarantee about CGM performance
  • Why peer-reviewed, independent evidence is the gold standard — and how little of what is cited meets it
  • How study design quality shapes what we actually know about CGM risk
  • Professor Moser's perspective as a researcher who designs and runs these studies

Guest: Professor Othmar Moser, Medical University of Graz, Austria. Leading figure in independent CGM accuracy study design and insulin-related exercise physiology research in type 1 diabetes.

Links:

  • Full show notes: https://theglucoseneverlies.com/episode-35-cgm-series-the-importance-of-cgm-accuracy-and-study-design-with-professor-othmar-moser/
  • CGM Guide Part 2 — Assessing CGM Accuracy: https://theglucoseneverlies.com/assessing-cgm-accuracy-performance/
  • CGM Guide Part 1 — How to Choose a CGM: https://theglucoseneverlies.com/select-continuous-glucose-monitor-cgm-understanding/
  • Episode 36 — DSN Forum: CGM Accuracy and ATTD 2025: https://theglucoseneverlies.com/episode-36-cgm-accuracy-dsn-forum/
  • Watch on YouTube: https://youtu.be/zTdTps42kQ8

Educational purposes only. Not medical advice. Always work with your diabetes care team.

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

CGM Series | The Glucose Never Lies® Podcast

CGM accuracy is usually described with a single number: MARD. But a low MARD can hide significant risk if the study behind it was poorly designed. Professor Othmar Moser — one of the leading independent CGM accuracy researchers — explains what study design actually determines, why meal and insulin challenges are non-negotiable, and what people with type 1 diabetes and clinicians should look for when evaluating any accuracy claim.

In this episode:

  • What MARD is and why it misleads when used in isolation
  • The five study design questions that determine what accuracy data actually means
  • Why 20/20 and 40/40 agreement rates reveal what MARD cannot
  • Why meal and insulin challenges are essential for real-world accuracy testing
  • What CE marking does and does not guarantee about CGM performance
  • Why peer-reviewed, independent evidence is the gold standard — and how little of what is cited meets it
  • How study design quality shapes what we actually know about CGM risk
  • Professor Moser's perspective as a researcher who designs and runs these studies

Guest: Professor Othmar Moser, Medical University of Graz, Austria. Leading figure in independent CGM accuracy study design and insulin-related exercise physiology research in type 1 diabetes.

Links:

  • Full show notes: https://theglucoseneverlies.com/episode-35-cgm-series-the-importance-of-cgm-accuracy-and-study-design-with-professor-othmar-moser/
  • CGM Guide Part 2 — Assessing CGM Accuracy: https://theglucoseneverlies.com/assessing-cgm-accuracy-performance/
  • CGM Guide Part 1 — How to Choose a CGM: https://theglucoseneverlies.com/select-continuous-glucose-monitor-cgm-understanding/
  • Episode 36 — DSN Forum: CGM Accuracy and ATTD 2025: https://theglucoseneverlies.com/episode-36-cgm-accuracy-dsn-forum/
  • Watch on YouTube: https://youtu.be/zTdTps42kQ8

Educational purposes only. Not medical advice. Always work with your diabetes care team.

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18893446 Mon, 23 Mar 2026 21:00:00 +0000 3575 35 full false 34 — Building High-Performance Type 1 Diabetes Care: Technology, Targets, and Equity (Dr Peter Adolfsson) 34 — Building High-Performance Type 1 Diabetes Care: Technology, Targets, and Equity (Dr Peter Adolfsson) Suggest guests or get in contact

How do some countries consistently achieve lower HbA1c and better outcomes in type 1 diabetes while others struggle — even with the same technologies?

In this episode, John Pemberton speaks with Dr Peter Adolfsson, paediatric diabetologist in Sweden and lead author of the ISPAD 2022 Exercise Guidelines, about what actually drives population-level improvements in type 1 diabetes care.

Full show notes:

https://theglucoseneverlies.com/episode-34-building-high-performance-type-1-diabetes-care-technology-targets-and-equity-dr-peter-adolfsson/

KEY TOPICS

• How Sweden’s national diabetes registry drives accountability and rapid improvement
 • Why structured onboarding and early follow-up are essential for CGM and AID success
 • The role of national collaboration between clinics to share best practice
 • Why the highest HbA1c group should often be first in line for AID systems
 • Moving toward time in tight range (3.9–7.8 mmol/L) as the next clinical target
• Equity in diabetes technology: checking subconscious bias with real data
• Why celebrating small improvements builds long-term engagement

WHAT YOU’LL LEARN

✓ Why early investment in education and follow-up changes long-term outcomes
 ✓ How national benchmarking between clinics improves diabetes care
 ✓ Why targets matter — changing what you measure changes what improves
 ✓ How to use AID systems strategically for people struggling with bolusing
 ✓ Why the first two years after diagnosis are a critical window for glycaemic outcomes
 ✓ The importance of psychology, social support, and multidisciplinary teams

FUTURE OF TYPE 1 DIABETES CARE

• AI-supported platforms that analyse CGM data continuously
 • Clinics responding earlier when glucose control deteriorates
 • Personalised therapy combining insulin with adjunct treatments (e.g., GLP-1RA)
 • More flexible care models where stable patients may need fewer clinic visits

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

How do some countries consistently achieve lower HbA1c and better outcomes in type 1 diabetes while others struggle — even with the same technologies?

In this episode, John Pemberton speaks with Dr Peter Adolfsson, paediatric diabetologist in Sweden and lead author of the ISPAD 2022 Exercise Guidelines, about what actually drives population-level improvements in type 1 diabetes care.

Full show notes:

https://theglucoseneverlies.com/episode-34-building-high-performance-type-1-diabetes-care-technology-targets-and-equity-dr-peter-adolfsson/

KEY TOPICS

• How Sweden’s national diabetes registry drives accountability and rapid improvement
 • Why structured onboarding and early follow-up are essential for CGM and AID success
 • The role of national collaboration between clinics to share best practice
 • Why the highest HbA1c group should often be first in line for AID systems
 • Moving toward time in tight range (3.9–7.8 mmol/L) as the next clinical target
• Equity in diabetes technology: checking subconscious bias with real data
• Why celebrating small improvements builds long-term engagement

WHAT YOU’LL LEARN

✓ Why early investment in education and follow-up changes long-term outcomes
 ✓ How national benchmarking between clinics improves diabetes care
 ✓ Why targets matter — changing what you measure changes what improves
 ✓ How to use AID systems strategically for people struggling with bolusing
 ✓ Why the first two years after diagnosis are a critical window for glycaemic outcomes
 ✓ The importance of psychology, social support, and multidisciplinary teams

FUTURE OF TYPE 1 DIABETES CARE

• AI-supported platforms that analyse CGM data continuously
 • Clinics responding earlier when glucose control deteriorates
 • Personalised therapy combining insulin with adjunct treatments (e.g., GLP-1RA)
 • More flexible care models where stable patients may need fewer clinic visits

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18788463 Wed, 04 Mar 2026 14:00:00 +0000 3062 34 full false 33 — Exercise Evidence for Females with T1D: Mind the Gap | Associate Professor Jane Yardley 33 — Exercise Evidence for Females with T1D: Mind the Gap | Associate Professor Jane Yardley Suggest guests or get in contact

Exercise guidelines for type 1 diabetes are built on research dominated by male participants. Professor Jane Yardley, a leading exercise physiologist, bridges the research gap between male and female exercise physiology in type 1 diabetes.

This conversation reveals why carbohydrate recommendations systematically overestimate female needs, how menstrual cycle phases alter insulin requirements during exercise, why peripheral hyperinsulinemia creates unique barriers to fat loss, and how fasted morning exercise offers a low-risk, high-reward strategy for improving insulin sensitivity and accessing fat stores.

Full show notes: https://theglucoseneverlies.com/females-exercise-t1d/

KEY TOPICS:
• Why ~60-70% of females experience luteal phase insulin resistance (10-50% increased needs)
• How AID systems struggle to keep up with rapid menstrual cycle changes
• Why per-kilogram carb recommendations overestimate female athletes' needs
• The peripheral hyperinsulinemia barrier: 4-8× higher insulin blocks fat release
• Fasted exercise: zero planning, minimal hypo risk, maximum fat burning
• Why muscle and bone health in your 20s-30s determines mobility in your 60s-80s
• Menopause transitions and accelerated cardiovascular risk

WHAT YOU'LL LEARN:
✓ Luteal phase exercise may require larger insulin adjustments
✓ Females use more fat as fuel — estrogen promotes fat oxidation
✓ Bolus insulin lasts 6 hours, not 2-4 (why "between meals" isn't truly fasted)
✓ Morning fasted exercise depletes glycogen and improves all-day insulin sensitivity
✓ How to overcome the fat loss barrier created by high peripheral insulin
✓ Why resistance training NOW prevents fractures and disability later
✓ Pregnancy exercise principles (sparse data, clear physiology)

PRACTICAL STRATEGIES:
→ Fasted morning exercise: roll out of bed, black coffee, go — no adjustments needed
→ Luteal phase: consider 60-70% basal cuts (not 50%) for postprandial exercise
→ Start with LESS carbohydrate than guidelines suggest, adjust based on YOUR response
→ Build peak muscle/bone by age 30 — you can't make up for lost time at retirement
→ Post-meal walks in pregnancy: 15-20 min keeps glucose <7.8 mmol/L without extra insulin

GUEST: Associate Professor Jane Yardley
University of Montreal & Montreal Clinical Research Institute

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Exercise guidelines for type 1 diabetes are built on research dominated by male participants. Professor Jane Yardley, a leading exercise physiologist, bridges the research gap between male and female exercise physiology in type 1 diabetes.

This conversation reveals why carbohydrate recommendations systematically overestimate female needs, how menstrual cycle phases alter insulin requirements during exercise, why peripheral hyperinsulinemia creates unique barriers to fat loss, and how fasted morning exercise offers a low-risk, high-reward strategy for improving insulin sensitivity and accessing fat stores.

Full show notes: https://theglucoseneverlies.com/females-exercise-t1d/

KEY TOPICS:
• Why ~60-70% of females experience luteal phase insulin resistance (10-50% increased needs)
• How AID systems struggle to keep up with rapid menstrual cycle changes
• Why per-kilogram carb recommendations overestimate female athletes' needs
• The peripheral hyperinsulinemia barrier: 4-8× higher insulin blocks fat release
• Fasted exercise: zero planning, minimal hypo risk, maximum fat burning
• Why muscle and bone health in your 20s-30s determines mobility in your 60s-80s
• Menopause transitions and accelerated cardiovascular risk

WHAT YOU'LL LEARN:
✓ Luteal phase exercise may require larger insulin adjustments
✓ Females use more fat as fuel — estrogen promotes fat oxidation
✓ Bolus insulin lasts 6 hours, not 2-4 (why "between meals" isn't truly fasted)
✓ Morning fasted exercise depletes glycogen and improves all-day insulin sensitivity
✓ How to overcome the fat loss barrier created by high peripheral insulin
✓ Why resistance training NOW prevents fractures and disability later
✓ Pregnancy exercise principles (sparse data, clear physiology)

PRACTICAL STRATEGIES:
→ Fasted morning exercise: roll out of bed, black coffee, go — no adjustments needed
→ Luteal phase: consider 60-70% basal cuts (not 50%) for postprandial exercise
→ Start with LESS carbohydrate than guidelines suggest, adjust based on YOUR response
→ Build peak muscle/bone by age 30 — you can't make up for lost time at retirement
→ Post-meal walks in pregnancy: 15-20 min keeps glucose <7.8 mmol/L without extra insulin

GUEST: Associate Professor Jane Yardley
University of Montreal & Montreal Clinical Research Institute

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18648959 Wed, 11 Feb 2026 15:00:00 +0000 4306 33 full false 32 — Menstrual Cycles & Type 1 Diabetes: The Gender Gap in Care | Dr. Cecilia Nobili 32 — Menstrual Cycles & Type 1 Diabetes: The Gender Gap in Care | Dr. Cecilia Nobili Suggest guests or get in contact

The menstrual cycle affects half of people with type 1 diabetes, yet it's nearly invisible in clinical guidelines, research, and technology design. Dr. Cecilia Nobili — a pediatric diabetology resident and researcher living with T1D — bridges the gap between lived experience and clinical evidence.

In this episode, Dr. Nobili shares findings from her observational study of 170 women, revealing how different insulin delivery systems handle monthly hormonal shifts, which phases create the biggest burden, and why this represents a genuine gender gap in diabetes care.

Full show notes: https://theglucoseneverlies.com/menstrual-cycle-t1d/ 

KEY TOPICS:
• Why 60% of women on MDI experience ≥5% drop in time in range during luteal phase
• How AID systems cut glucose deterioration in half — but aren't perfect
• Why hypoglycemia when bleeding starts is often more burdensome than luteal phase highs
• Practical strategies for each AID system (780G, Omnipod 5, Control-IQ, CamAPS FX) and MDI
• The progesterone effect: why insulin resistance peaks before your period
• How to anticipate changes and adjust proactively rather than reactively
• Why this should be built into algorithms (but isn't)

WHAT YOU'LL LEARN:
✓ The five phases of the menstrual cycle and their glucose impact
✓ Which AID systems show the most stability across cycle phases
✓ Target adjustments, boost functions, and profile switches that actually work
✓ Why pre-bolusing matters more during the luteal phase
✓ How to prevent the hypoglycemia tsunami when bleeding starts
✓ Why one bad day per month is not catastrophic

Dr. Nobili's research is funded by a grant and represents the first multi-center study specifically examining menstrual cycle glucose patterns across insulin delivery modalities.

This episode provides the structured guidance that should exist in every diabetes clinic — but doesn't.

GUEST: Dr. Cecilia Nobili
Pediatric Diabetology Resident, Turin, Italy
Living with T1D 
Multi-center researcher on menstrual cycles and glucose control


Full show notes, practical checklists, and related episodes: https://theglucoseneverlies.com/menstrual-cycle-t1d/ 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

The menstrual cycle affects half of people with type 1 diabetes, yet it's nearly invisible in clinical guidelines, research, and technology design. Dr. Cecilia Nobili — a pediatric diabetology resident and researcher living with T1D — bridges the gap between lived experience and clinical evidence.

In this episode, Dr. Nobili shares findings from her observational study of 170 women, revealing how different insulin delivery systems handle monthly hormonal shifts, which phases create the biggest burden, and why this represents a genuine gender gap in diabetes care.

Full show notes: https://theglucoseneverlies.com/menstrual-cycle-t1d/ 

KEY TOPICS:
• Why 60% of women on MDI experience ≥5% drop in time in range during luteal phase
• How AID systems cut glucose deterioration in half — but aren't perfect
• Why hypoglycemia when bleeding starts is often more burdensome than luteal phase highs
• Practical strategies for each AID system (780G, Omnipod 5, Control-IQ, CamAPS FX) and MDI
• The progesterone effect: why insulin resistance peaks before your period
• How to anticipate changes and adjust proactively rather than reactively
• Why this should be built into algorithms (but isn't)

WHAT YOU'LL LEARN:
✓ The five phases of the menstrual cycle and their glucose impact
✓ Which AID systems show the most stability across cycle phases
✓ Target adjustments, boost functions, and profile switches that actually work
✓ Why pre-bolusing matters more during the luteal phase
✓ How to prevent the hypoglycemia tsunami when bleeding starts
✓ Why one bad day per month is not catastrophic

Dr. Nobili's research is funded by a grant and represents the first multi-center study specifically examining menstrual cycle glucose patterns across insulin delivery modalities.

This episode provides the structured guidance that should exist in every diabetes clinic — but doesn't.

GUEST: Dr. Cecilia Nobili
Pediatric Diabetology Resident, Turin, Italy
Living with T1D 
Multi-center researcher on menstrual cycles and glucose control


Full show notes, practical checklists, and related episodes: https://theglucoseneverlies.com/menstrual-cycle-t1d/ 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18648540 Mon, 09 Feb 2026 13:00:00 +0000 3284 32 full false 31 — Prof Scott on pregnancy with type 1 diabetes: from pre-conception planning to postpartum care 31 — Prof Scott on pregnancy with type 1 diabetes: from pre-conception planning to postpartum care Suggest guests or get in contact

Professor Eleanor Scott, one of the UK's leading experts in pregnancy and diabetes, provides the evidence-based roadmap that cuts through the noise. 

Full Show notes: https://theglucoseneverlies.com/pregnancy-t1d/

This episode covers the complete journey: pre-conception planning (why HbA1c <48 mmol/mol and 70% time in pregnancy range matters), the chaos of first trimester insulin sensitivity and hypos, the dramatic insulin resistance of trimesters two and three (where insulin needs can increase 3-5× baseline), and the instant drop in insulin requirements after delivery.

Professor Scott explains why the pregnancy glucose target is tighter (3.5-7.8 mmol/L / 63-140 mg/dL) — babies are extremely sensitive to raised glucose, which increases risks of miscarriage, congenital malformations, preterm delivery, and large babies requiring neonatal intensive care. She also offers reassurance: if pregnancy is unplanned or glucose control isn't optimal at conception, early intervention still makes a substantial difference. Absolute risk of complications remains around 10% even with high HbA1c at conception — not inevitable.

The technology discussion is critical: CGM is non-negotiable  But not all hybrid closed-loop systems are equal. CamAPS FX is the only system with robust RCT evidence (ADAPT trial) showing improved time in range, reduced gestational weight gain, smaller babies, and less maternal burden. It was developed specifically for pregnancy with adaptive algorithms and a personal glucose target as low as 4.4 mmol/L. The Medtronic 780G has a CE mark for pregnancy but didn't improve time in range in trials. Other systems aren't studied or indicated for pregnancy.

Practical strategies include pre-bolusing 15-20 minutes, choosing mixed meals over high-GI foods, walking after eating, moderate carbohydrate intake (30-40%), and building routine to help algorithms (and your brain) adapt to rapid changes.

For show notes, resources, and full transcript: https://theglucoseneverlies.com/pregnancy-t1d/

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Professor Eleanor Scott, one of the UK's leading experts in pregnancy and diabetes, provides the evidence-based roadmap that cuts through the noise. 

Full Show notes: https://theglucoseneverlies.com/pregnancy-t1d/

This episode covers the complete journey: pre-conception planning (why HbA1c <48 mmol/mol and 70% time in pregnancy range matters), the chaos of first trimester insulin sensitivity and hypos, the dramatic insulin resistance of trimesters two and three (where insulin needs can increase 3-5× baseline), and the instant drop in insulin requirements after delivery.

Professor Scott explains why the pregnancy glucose target is tighter (3.5-7.8 mmol/L / 63-140 mg/dL) — babies are extremely sensitive to raised glucose, which increases risks of miscarriage, congenital malformations, preterm delivery, and large babies requiring neonatal intensive care. She also offers reassurance: if pregnancy is unplanned or glucose control isn't optimal at conception, early intervention still makes a substantial difference. Absolute risk of complications remains around 10% even with high HbA1c at conception — not inevitable.

The technology discussion is critical: CGM is non-negotiable  But not all hybrid closed-loop systems are equal. CamAPS FX is the only system with robust RCT evidence (ADAPT trial) showing improved time in range, reduced gestational weight gain, smaller babies, and less maternal burden. It was developed specifically for pregnancy with adaptive algorithms and a personal glucose target as low as 4.4 mmol/L. The Medtronic 780G has a CE mark for pregnancy but didn't improve time in range in trials. Other systems aren't studied or indicated for pregnancy.

Practical strategies include pre-bolusing 15-20 minutes, choosing mixed meals over high-GI foods, walking after eating, moderate carbohydrate intake (30-40%), and building routine to help algorithms (and your brain) adapt to rapid changes.

For show notes, resources, and full transcript: https://theglucoseneverlies.com/pregnancy-t1d/

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18648032 Mon, 09 Feb 2026 12:00:00 +0000 4883 31 full false 30 — Educating on the algorithms behind diabetes devices 30 — Educating on the algorithms behind diabetes devices Suggest guests or get in contact

In this episode of Glucose Never Lies, John Pemberton welcomes Dr. Inge Van Boxelaer, endocrinologist and founder of Diabetotech, an independent education platform for diabetes technology. Together, they explore the critical role of education in maximizing the benefits of devices like continuous glucose monitors (CGMs), insulin pumps, and automated insulin delivery (AID) systems.

Dr. Van Boxelaer shares her journey from clinical practice to creating Diabetotech, highlighting how access to technology isn’t enough—patients and healthcare professionals need structured, unbiased, and up-to-date training. The conversation covers how Diabetotech delivers short, modular courses, device comparisons, and CPD-accredited content, helping clinicians, educators, and people living with diabetes gain confidence and improve outcomes.

Full Show notes: https://theglucoseneverlies.com/30-diabetotech-education/

Key topics include:

  • Overcoming educational barriers to adopting new diabetes technologies
  • The evolution of AID systems and CGMs, and their impact on daily management
  • How flipped learning and modular education can save clinician time while improving patient competency
  • Independent, consistent, and regularly updated resources for clinicians, patients, and care teams

Whether you’re a healthcare professional, a person living with diabetes, or part of a care team, this episode highlights why understanding the technology is as important as having it. Dr. Van Boxelaer also shares her vision for the future of diabetes education and how accessible learning can support better outcomes and fewer complications.

Explore Diabetotech and its resources at https://www.diabetotech.com/

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

In this episode of Glucose Never Lies, John Pemberton welcomes Dr. Inge Van Boxelaer, endocrinologist and founder of Diabetotech, an independent education platform for diabetes technology. Together, they explore the critical role of education in maximizing the benefits of devices like continuous glucose monitors (CGMs), insulin pumps, and automated insulin delivery (AID) systems.

Dr. Van Boxelaer shares her journey from clinical practice to creating Diabetotech, highlighting how access to technology isn’t enough—patients and healthcare professionals need structured, unbiased, and up-to-date training. The conversation covers how Diabetotech delivers short, modular courses, device comparisons, and CPD-accredited content, helping clinicians, educators, and people living with diabetes gain confidence and improve outcomes.

Full Show notes: https://theglucoseneverlies.com/30-diabetotech-education/

Key topics include:

  • Overcoming educational barriers to adopting new diabetes technologies
  • The evolution of AID systems and CGMs, and their impact on daily management
  • How flipped learning and modular education can save clinician time while improving patient competency
  • Independent, consistent, and regularly updated resources for clinicians, patients, and care teams

Whether you’re a healthcare professional, a person living with diabetes, or part of a care team, this episode highlights why understanding the technology is as important as having it. Dr. Van Boxelaer also shares her vision for the future of diabetes education and how accessible learning can support better outcomes and fewer complications.

Explore Diabetotech and its resources at https://www.diabetotech.com/

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18623864 Wed, 04 Feb 2026 13:00:00 +0000 1914 30 full false 29 — The Behaviour Change Playbook for Type 1 Diabetes 29 — The Behaviour Change Playbook for Type 1 Diabetes Suggest guests or get in contact

Five principles that make change more likely to stick

John Pemberton is joined by Vanessa Haydock (The Diabetic Health Coach). Background in psychology and applied behaviour analysis, certified behaviour analyst, personal trainer, and coach supporting people with type 1 diabetes through sustainable behaviour change.

Full notes: https://theglucoseneverlies.com/beahviour-change-t1d/

This conversation lays out a practical behaviour change playbook grounded in psychology, lived experience, and the realities of diabetes physiology.

00:00 — Why this conversation matters — why willpower alone fails.

02:45 — Vanessa’s story: diagnosis, denial, and turning point
Growing up with type 1 diabetes, rebellion, burnout, retinopathy as an emotional trigger, and how behaviour change (not perfection) transformed Vanessa’s relationship with diabetes.

16:45 — Principle 1: Design beats discipline
Why willpower is finite in type 1 diabetes, and how reducing decision load through systems, defaults, and realistic goals makes change more sustainable.

30:35 — Principle 2: Cues beat grit
How environment and prompts outperform memory — from insulin timing to daily routines — and why piggybacking on existing habits works.

39:20 — Principle 3: Reduce threat before effort
How fear, pressure, and perceived failure drive avoidance behaviours — and why lowering the threat level is essential before increasing effort.

45:10 — Principle 4: Hawk or Owl, Carrot or Stick
Choosing the right style of accountability and feedback — frequent vs spaced, direct vs gentle — and why mismatch derails progress.

51:15 — Principle 5: Community support, not shame
Why small, safe communities outperform noisy online spaces, and how shared reality reduces isolation and burnout.

59:40 — Pulling it together: a practical playbook for 2026
How to apply the five principles deliberately, without perfectionism or guilt.

Find Vanessa at:

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Five principles that make change more likely to stick

John Pemberton is joined by Vanessa Haydock (The Diabetic Health Coach). Background in psychology and applied behaviour analysis, certified behaviour analyst, personal trainer, and coach supporting people with type 1 diabetes through sustainable behaviour change.

Full notes: https://theglucoseneverlies.com/beahviour-change-t1d/

This conversation lays out a practical behaviour change playbook grounded in psychology, lived experience, and the realities of diabetes physiology.

00:00 — Why this conversation matters — why willpower alone fails.

02:45 — Vanessa’s story: diagnosis, denial, and turning point
Growing up with type 1 diabetes, rebellion, burnout, retinopathy as an emotional trigger, and how behaviour change (not perfection) transformed Vanessa’s relationship with diabetes.

16:45 — Principle 1: Design beats discipline
Why willpower is finite in type 1 diabetes, and how reducing decision load through systems, defaults, and realistic goals makes change more sustainable.

30:35 — Principle 2: Cues beat grit
How environment and prompts outperform memory — from insulin timing to daily routines — and why piggybacking on existing habits works.

39:20 — Principle 3: Reduce threat before effort
How fear, pressure, and perceived failure drive avoidance behaviours — and why lowering the threat level is essential before increasing effort.

45:10 — Principle 4: Hawk or Owl, Carrot or Stick
Choosing the right style of accountability and feedback — frequent vs spaced, direct vs gentle — and why mismatch derails progress.

51:15 — Principle 5: Community support, not shame
Why small, safe communities outperform noisy online spaces, and how shared reality reduces isolation and burnout.

59:40 — Pulling it together: a practical playbook for 2026
How to apply the five principles deliberately, without perfectionism or guilt.

Find Vanessa at:

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18492347 Mon, 12 Jan 2026 08:00:00 +0000 3969 29 full false 28 — Then Glucose Never Lies 2025 in Review: Chaos → Clarity 28 — Then Glucose Never Lies 2025 in Review: Chaos → Clarity Suggest guests or get in contact

Host: John Pemberton, RD
Guest: Anjanee Kohli, RD MNutr

2025 was a formative year for The Glucose Never Lies® Podcast. Not because everything went smoothly — but because repeated exposure to real-world problems forced clearer models, sharper questions, and fewer illusions.

In this year-in-review episode, John Pemberton is joined by Anjanee Kohli — diabetes specialist dietitian, creative lead, and co-director at Glucose Never Lies — for an honest audit of what the podcast set out to do, what it actually delivered, where their thinking evolved, and where uncertainty remains.

Together, they revisit the core themes that kept resurfacing across episodes in 2025: insulin timing and dose over tactics, the liver’s central role, exercise variability, device and algorithm trade-offs, accessibility, and the gap between theoretical optimisation and lived experience with type 1 diabetes.

This conversation is not a highlights reel. It’s a reflective pause — stripping ideas back to what survived contact with reality, and clarifying what Glucose Never Lies is deliberately carrying forward into 2026.

Read the full episode page, explore linked episodes, resources, and references:
 https://theglucoseneverlies.com/episode-28-2025-in-review/

What this episode covers

  • Why 2025 required a shift from tactics to principles
  • What repeated real-world patterns taught us about insulin, exercise, and devices
  • Where technology helps — and where trade-offs remain unavoidable
  • Episodes and resources worth revisiting depending on your current challenge
  • What changed our minds, and what we’re still uncertain about
  • What Glucose Never Lies is committing to — and leaving behind — in 2026

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Host: John Pemberton, RD
Guest: Anjanee Kohli, RD MNutr

2025 was a formative year for The Glucose Never Lies® Podcast. Not because everything went smoothly — but because repeated exposure to real-world problems forced clearer models, sharper questions, and fewer illusions.

In this year-in-review episode, John Pemberton is joined by Anjanee Kohli — diabetes specialist dietitian, creative lead, and co-director at Glucose Never Lies — for an honest audit of what the podcast set out to do, what it actually delivered, where their thinking evolved, and where uncertainty remains.

Together, they revisit the core themes that kept resurfacing across episodes in 2025: insulin timing and dose over tactics, the liver’s central role, exercise variability, device and algorithm trade-offs, accessibility, and the gap between theoretical optimisation and lived experience with type 1 diabetes.

This conversation is not a highlights reel. It’s a reflective pause — stripping ideas back to what survived contact with reality, and clarifying what Glucose Never Lies is deliberately carrying forward into 2026.

Read the full episode page, explore linked episodes, resources, and references:
 https://theglucoseneverlies.com/episode-28-2025-in-review/

What this episode covers

  • Why 2025 required a shift from tactics to principles
  • What repeated real-world patterns taught us about insulin, exercise, and devices
  • Where technology helps — and where trade-offs remain unavoidable
  • Episodes and resources worth revisiting depending on your current challenge
  • What changed our minds, and what we’re still uncertain about
  • What Glucose Never Lies is committing to — and leaving behind — in 2026

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18446702 Sat, 03 Jan 2026 15:00:00 +0000 3850 28 full false 27 — T1D Looping Blind: Making the Impossible Possible Together 27 — T1D Looping Blind: Making the Impossible Possible Together Suggest guests or get in contact

Host: John Pemberton, RD
Guests: Roger Moore & Robin Lucciantonio

Roger has lived with type 1 diabetes since age two and has been totally blind for more than 35 years. While automated insulin delivery (AID) has transformed safety and glucose stability for many people with type 1 diabetes, most systems remain inaccessible without sight.

In this Inspiring Stories episode of The Glucose Never Lies® Podcast, John Pemberton speaks with Roger Moore and diabetes educator Robin Lucciantonio about how they refused to accept that limitation. Using the open-source Loop system with iPhone VoiceOver, a careful stepwise rollout (simulator → saline → insulin), and a handcrafted tactile pod-filling station, Roger achieved full autonomy with AID.

This conversation isn’t about technology alone. It’s about accessibility as a safety requirement, not a convenience feature — and what becomes possible when clinicians stay open-minded and systems are built around real people rather than default users.

Read the full episode page and see the setup:
https://theglucoseneverlies.com/looping-blind/

What this episode covers

  • Living with type 1 diabetes without visual feedback
  • Why most commercial AID systems are inaccessible without sight
  • Using Loop and VoiceOver for non-visual insulin delivery
  • Simulator and saline trials to reduce risk before going live
  • Designing a tactile pod-filling station for safe, repeatable insulin delivery
  • Outcomes that matter: reduced hypoglycaemia, autonomy, and dignity

Disclaimer
This content is for informational purposes only and does not constitute medical advice. It does not create a therapeutic relationship. DIY automated insulin delivery systems carry real risks and require appropriate training, oversight, and contingency planning.

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Host: John Pemberton, RD
Guests: Roger Moore & Robin Lucciantonio

Roger has lived with type 1 diabetes since age two and has been totally blind for more than 35 years. While automated insulin delivery (AID) has transformed safety and glucose stability for many people with type 1 diabetes, most systems remain inaccessible without sight.

In this Inspiring Stories episode of The Glucose Never Lies® Podcast, John Pemberton speaks with Roger Moore and diabetes educator Robin Lucciantonio about how they refused to accept that limitation. Using the open-source Loop system with iPhone VoiceOver, a careful stepwise rollout (simulator → saline → insulin), and a handcrafted tactile pod-filling station, Roger achieved full autonomy with AID.

This conversation isn’t about technology alone. It’s about accessibility as a safety requirement, not a convenience feature — and what becomes possible when clinicians stay open-minded and systems are built around real people rather than default users.

Read the full episode page and see the setup:
https://theglucoseneverlies.com/looping-blind/

What this episode covers

  • Living with type 1 diabetes without visual feedback
  • Why most commercial AID systems are inaccessible without sight
  • Using Loop and VoiceOver for non-visual insulin delivery
  • Simulator and saline trials to reduce risk before going live
  • Designing a tactile pod-filling station for safe, repeatable insulin delivery
  • Outcomes that matter: reduced hypoglycaemia, autonomy, and dignity

Disclaimer
This content is for informational purposes only and does not constitute medical advice. It does not create a therapeutic relationship. DIY automated insulin delivery systems carry real risks and require appropriate training, oversight, and contingency planning.

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18423334 Sun, 28 Dec 2025 23:00:00 +0000 2544 27 full false 26 – Building a Diabetes Community Through Vulnerability, Movement and Mindset (Diabetes with Mily) 26 – Building a Diabetes Community Through Vulnerability, Movement and Mindset (Diabetes with Mily) Suggest guests or get in contact

Host: John Pemberton, RD
Guest: Diabetes with Milly (Milly)

Episode page: Detailed show notes

In this episode, Milly joins John to explore how real community forms when people with type 1 diabetes feel safe enough to be vulnerable. Diagnosed during lockdown and thrown into DKA in the final year of her biology degree, Milly rebuilt her life through movement, self-experimenting with strength training, discovering yoga, and eventually travelling alone to India for formal practice in breathwork, mindset and nervous-system regulation.

What began as a personal diary on Instagram became Diabetes with Milly — a space where 10,000+ people find honesty, humour and connection, and where the Glucose Gals WhatsApp community now supports hundreds of women navigating type 1 diabetes, menstrual cycles, trauma echoes, and real-life blood glucose chaos.

This conversation sits firmly “Beyond the Numbers”: the human reality of diagnosis, burnout, highs that trigger old trauma, rebuilding confidence, and how movement and mindfulness can reshape the emotional experience of living with the condition.

Your community is not optional — it is protective infrastructure.

What This Episode Covers

  • Diagnosis in lockdown: DKA, isolation, and learning to manage T1D without real-world support
  • Sport to strength training: using exercise as both therapy and education
  • Yoga, India, breathwork and regulating the panic response during hypos
  • Trauma memory: why highs can trigger the emotional weight of diagnosis
  • Building an online presence through vulnerability, not perfection
  • Creating the Glucose Gals WhatsApp community (250+ women)
  • Women’s health, menstrual cycles and why female physiology in T1D is so understudied
  • Milly’s plans for a new master’s → PhD in women’s exercise physiology
  • The future: UK meet-ups, movement spaces, and combining strength + yoga for holistic T1D support

Key Insights

Vulnerability builds community.
People don’t gather around perfect numbers — they gather around honesty.

Movement changes glucose, but also mindset.
Strength training, yoga and breathwork each shape the physiological and emotional response to hypo/hyper stress.

Trauma echoes are real.
Diagnosis anniversaries, unexplained highs and body sensations can resurface early memories; normalising this reduces shame.

Representation matters.
Women with T1D need research that reflects menstrual cycles, hormonal phases and real-world fluctuations.

People need people.
Where clinic appointments end, community begins — and fills the gap between guideline and lived reality.

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Host: John Pemberton, RD
Guest: Diabetes with Milly (Milly)

Episode page: Detailed show notes

In this episode, Milly joins John to explore how real community forms when people with type 1 diabetes feel safe enough to be vulnerable. Diagnosed during lockdown and thrown into DKA in the final year of her biology degree, Milly rebuilt her life through movement, self-experimenting with strength training, discovering yoga, and eventually travelling alone to India for formal practice in breathwork, mindset and nervous-system regulation.

What began as a personal diary on Instagram became Diabetes with Milly — a space where 10,000+ people find honesty, humour and connection, and where the Glucose Gals WhatsApp community now supports hundreds of women navigating type 1 diabetes, menstrual cycles, trauma echoes, and real-life blood glucose chaos.

This conversation sits firmly “Beyond the Numbers”: the human reality of diagnosis, burnout, highs that trigger old trauma, rebuilding confidence, and how movement and mindfulness can reshape the emotional experience of living with the condition.

Your community is not optional — it is protective infrastructure.

What This Episode Covers

  • Diagnosis in lockdown: DKA, isolation, and learning to manage T1D without real-world support
  • Sport to strength training: using exercise as both therapy and education
  • Yoga, India, breathwork and regulating the panic response during hypos
  • Trauma memory: why highs can trigger the emotional weight of diagnosis
  • Building an online presence through vulnerability, not perfection
  • Creating the Glucose Gals WhatsApp community (250+ women)
  • Women’s health, menstrual cycles and why female physiology in T1D is so understudied
  • Milly’s plans for a new master’s → PhD in women’s exercise physiology
  • The future: UK meet-ups, movement spaces, and combining strength + yoga for holistic T1D support

Key Insights

Vulnerability builds community.
People don’t gather around perfect numbers — they gather around honesty.

Movement changes glucose, but also mindset.
Strength training, yoga and breathwork each shape the physiological and emotional response to hypo/hyper stress.

Trauma echoes are real.
Diagnosis anniversaries, unexplained highs and body sensations can resurface early memories; normalising this reduces shame.

Representation matters.
Women with T1D need research that reflects menstrual cycles, hormonal phases and real-world fluctuations.

People need people.
Where clinic appointments end, community begins — and fills the gap between guideline and lived reality.

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18263603 Tue, 09 Dec 2025 09:00:00 +0000 2355 26 full false 25 — Partying with T1D (Alcohol Edition) 25 — Partying with T1D (Alcohol Edition) Suggest guests or get in contact

In this episode, John Pemberton and Dr Dessi Zaharieva open a transparent, evidence-based conversation about alcohol, nightlife, festivals, hypos, and harm-reduction for people living with Type 1 Diabetes.

Full episode page 

FAQ: Alcohol & Type 1 Diabetes

Alcohol suppresses hepatic glucose output, disrupts REM sleep, increases overnight hypo risk, and affects metabolism differently across single-night and multi-day events. This episode walks through the mechanisms, the patterns, and the practical adjustments that help people stay safer.

What we cover:
• Alcohol’s effects on the liver and glucose release
• Why glucagon often fails
• Why memory disappears after drinking
• Night-one vs multi-night physiology
• Basal adjustments, Activity Mode, manual mode and MDI
• Festival strategies and hypo prevention
• How parents and clinicians can talk about alcohol without shame

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

In this episode, John Pemberton and Dr Dessi Zaharieva open a transparent, evidence-based conversation about alcohol, nightlife, festivals, hypos, and harm-reduction for people living with Type 1 Diabetes.

Full episode page 

FAQ: Alcohol & Type 1 Diabetes

Alcohol suppresses hepatic glucose output, disrupts REM sleep, increases overnight hypo risk, and affects metabolism differently across single-night and multi-day events. This episode walks through the mechanisms, the patterns, and the practical adjustments that help people stay safer.

What we cover:
• Alcohol’s effects on the liver and glucose release
• Why glucagon often fails
• Why memory disappears after drinking
• Night-one vs multi-night physiology
• Basal adjustments, Activity Mode, manual mode and MDI
• Festival strategies and hypo prevention
• How parents and clinicians can talk about alcohol without shame

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18202949 Sun, 30 Nov 2025 15:00:00 +0000 4121 25 full false 24 — Skincare, Sensors & Smarter AID Algorithms for Type 1 Diabetes 24 — Skincare, Sensors & Smarter AID Algorithms for Type 1 Diabetes Suggest guests or get in contact

Host: John Pemberton, RD
Guest: Dr Laurel Messer, PhD, RN 

Epidose page - Detailed show notes

Episode FAQ - Dr Messer answers the FAQ's (free Downlaod)

In this episode, Dr Laurel Messer joins John to break down the real science behind skin integrity, sensor performance, and the hidden link between skincare and safer automation. Drawing on leading research from the Barbara Davis Center, the Panther Program, and international AID consensus work, this conversation reframes device wear as both a biological and behavioural skillset.  

Your skin is not decoration — it is life-critical infrastructure.

What This Episode Covers 

  • Why device-related skin issues are common, predictable, and preventable
  • Mechanical vs chemical irritation, and how to distinguish both from allergic dermatitis
  • The “Soap–Water–Dry → Rotate → Low & Slow” skin-protection framework
  • Why skin damage leads to noisy CGM data and poor insulin absorption
  • How to prepare skin for CGM and pump wear in children, teens, and adults
  • Practical barrier strategies: wipes, films, and hydrocolloids
  • Understanding Control-IQ: why the correction factor is the SUPERPOWER
  • Time-block insulin tuning for evening surges, alcohol, illness, and real-life
  • The future of Tandem: Control-IQ+, Mobi, patch options, & Libre 3+ 

Key Insights 

Skincare is diabetes care.
Healthy skin leads to better signal quality, fewer dropouts, more predictable insulin delivery, and improved algorithm stability. 

Rotation must be broader than most people think.
Use 6–10 zones and give each at least a week off. Children need even more structure due to limited real estate. 

Removal is where most damage occurs.
Dr Messer emphasises a wound-care approach: oil-based loosening, supporting the skin, and folding adhesives back on themselves — never pulling upward. 

Allergy and irritation are not the same problem.
Irritation improves with barriers and technique; allergy is reproducible, blistering, intensely itchy, and requires dermatology support and sometimes device change. 

Control-IQ’s performance hinge is the correction factor.
Across 20,000+ users, strengthening the correction factor improved responsiveness and time-in-range without increasing hypoglycaemia.  

Epidose page - Detailed show notes

Episode FAQ - Downlaod the best bits as Laurel answers the FAQ's 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Host: John Pemberton, RD
Guest: Dr Laurel Messer, PhD, RN 

Epidose page - Detailed show notes

Episode FAQ - Dr Messer answers the FAQ's (free Downlaod)

In this episode, Dr Laurel Messer joins John to break down the real science behind skin integrity, sensor performance, and the hidden link between skincare and safer automation. Drawing on leading research from the Barbara Davis Center, the Panther Program, and international AID consensus work, this conversation reframes device wear as both a biological and behavioural skillset.  

Your skin is not decoration — it is life-critical infrastructure.

What This Episode Covers 

  • Why device-related skin issues are common, predictable, and preventable
  • Mechanical vs chemical irritation, and how to distinguish both from allergic dermatitis
  • The “Soap–Water–Dry → Rotate → Low & Slow” skin-protection framework
  • Why skin damage leads to noisy CGM data and poor insulin absorption
  • How to prepare skin for CGM and pump wear in children, teens, and adults
  • Practical barrier strategies: wipes, films, and hydrocolloids
  • Understanding Control-IQ: why the correction factor is the SUPERPOWER
  • Time-block insulin tuning for evening surges, alcohol, illness, and real-life
  • The future of Tandem: Control-IQ+, Mobi, patch options, & Libre 3+ 

Key Insights 

Skincare is diabetes care.
Healthy skin leads to better signal quality, fewer dropouts, more predictable insulin delivery, and improved algorithm stability. 

Rotation must be broader than most people think.
Use 6–10 zones and give each at least a week off. Children need even more structure due to limited real estate. 

Removal is where most damage occurs.
Dr Messer emphasises a wound-care approach: oil-based loosening, supporting the skin, and folding adhesives back on themselves — never pulling upward. 

Allergy and irritation are not the same problem.
Irritation improves with barriers and technique; allergy is reproducible, blistering, intensely itchy, and requires dermatology support and sometimes device change. 

Control-IQ’s performance hinge is the correction factor.
Across 20,000+ users, strengthening the correction factor improved responsiveness and time-in-range without increasing hypoglycaemia.  

Epidose page - Detailed show notes

Episode FAQ - Downlaod the best bits as Laurel answers the FAQ's 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18195371 Sun, 23 Nov 2025 14:00:00 +0000 3627 24 full false 23 — From Diabetes Brunches to Bali by Creating a Type 1 Diabetes Community with Dr Temi Olonisakin 23 — From Diabetes Brunches to Bali by Creating a Type 1 Diabetes Community with Dr Temi Olonisakin Suggest guests or get in contact

Join John Pemberton as he sits down with Dr Temi Olonisakin — the doctor who turned a lonely Type 1 diabetes diagnosis at 17 into a movement of connection, confidence, and pancakes.

From small brunch tables in London to dreams of Bali gatherings, Temi’s story shows how joy, representation, and community can change what it means to live with diabetes.

How one young doctor turned isolation into connection — building a joyful, inclusive community for people living with Type 1 diabetes.

Diagnosed at 17, Temi knows the isolation that hits just as independence begins. Years later she began bringing people together — from one-to-one coffees to full-scale Diabetes Brunch Live events — mixing friendship, advocacy, and education with a healthy side of pancakes.

It’s not about brunch. It’s about belonging, visibility, and joy.

Say hello to Temi on Instagram @temidiabeticdoctor and join her for Brunch!

Full show notes and links
 
Chapters

00:00 Diagnosed at 17 — the lonely years
 05:30 First coffees → first brunch
 12:20 From 9 to 26 — growth & facilitation
 16:40 “Bottomless brunches” & normalising spikes
 21:30 Brunch Abroad dreams
 24:30 Beyond London — plans for the North
 25:50 Doctoring & sustainable work
 31:20 Advocacy wins — getting the right tech
 38:30 Representation & equity
 45:40 What services for teens miss
 47:50 Wrap-up & reflections

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Join John Pemberton as he sits down with Dr Temi Olonisakin — the doctor who turned a lonely Type 1 diabetes diagnosis at 17 into a movement of connection, confidence, and pancakes.

From small brunch tables in London to dreams of Bali gatherings, Temi’s story shows how joy, representation, and community can change what it means to live with diabetes.

How one young doctor turned isolation into connection — building a joyful, inclusive community for people living with Type 1 diabetes.

Diagnosed at 17, Temi knows the isolation that hits just as independence begins. Years later she began bringing people together — from one-to-one coffees to full-scale Diabetes Brunch Live events — mixing friendship, advocacy, and education with a healthy side of pancakes.

It’s not about brunch. It’s about belonging, visibility, and joy.

Say hello to Temi on Instagram @temidiabeticdoctor and join her for Brunch!

Full show notes and links
 
Chapters

00:00 Diagnosed at 17 — the lonely years
 05:30 First coffees → first brunch
 12:20 From 9 to 26 — growth & facilitation
 16:40 “Bottomless brunches” & normalising spikes
 21:30 Brunch Abroad dreams
 24:30 Beyond London — plans for the North
 25:50 Doctoring & sustainable work
 31:20 Advocacy wins — getting the right tech
 38:30 Representation & equity
 45:40 What services for teens miss
 47:50 Wrap-up & reflections

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18087310 Tue, 28 Oct 2025 05:00:00 +0000 2920 Type 1 diabetes, diabetes community, diabetes brunch, Dr Temi Olonisakin, lived experience, representation in diabetes, diabetes advocacy, CGM, continuous glucose monitoring, AID systems, insulin pumps, hybrid closed loop, peer support, diabetes education 23 full false 22 — From Diabetes Burnout to the CGM Access Blueprint — Kirsten de Klerk (South Africa) 22 — From Diabetes Burnout to the CGM Access Blueprint — Kirsten de Klerk (South Africa) Suggest guests or get in contact

When sixteen-year-old Kirsten de Klerk was diagnosed with type 1 diabetes, she asked how long she’d have to live like this. Her doctor replied, “Every day for the rest of your life.”

Years later, that sentence became the fuel for change.

Sign the CGM Access Petition: In less than one-minute, you can change global access to CGM forever.

In this episode, John Pemberton talks with Kirsten about her journey from diabetes burnout to national advocacy, and how her work is now shaping a CGM Access Blueprint for South Africa — a model that could influence global policy.

Episode 22: show notes and links and consider buying the GNL a Coffee to the podcast independent.

They discuss:

  • The emotional toll of diabetes burnout and the power of community.
  • How the #LetterToMyDiabetes movement sparked a nationwide campaign.
  • The reality of access inequality — 85 % of South Africans rely on public healthcare with only a few test strips a day.
  • The creation of SA Diabetes Advocacy, gathering 14 000+ petition signatures for CGM funding.
  • Why access without accuracy is false progress — and how unregulated devices put people at risk.

Kirsten and John explore what happens when lived experience meets evidence, and how persistence — not privilege — drives real change.

Together they outline three truths that every policymaker, clinician, and person with diabetes should understand:

  1. Not all CGMs are created equally.
    Some systems are clinically validated for insulin dosing; others are not. Price competition must not compromise safety.
  2. Inaccuracy harms you now.
    When CGMs fail to detect highs or lows, real people are put at immediate risk.
  3. Inaccuracy harms you later.
    CGMs that systematically under- or over-report glucose create false reassurance — “70% time-in-range on one device might be 60% on another.”

Sign the CGM Access Petition: In less than one-minute, you can change global access to CGM forever.

Links & Resources:
🌍 Sign the CGM Access Petition (South Africa)

📊 DSN Forum UK – CGM Comparison Chart

🔬 FIND Diagnostics – CGM Accuracy Factsheet

📘 GNL FAQ – CGM Regulation & Comparator Bias

📱 Follow Kirsten → @everydayisdiabetesday
| @sadiabetesadvocacy

🎧 Listen, learn, and share.
The CGM Access Blueprint begins in South Africa — but its lessons apply everywhere.

Episode 22: show notes and links and consider buying the GNL a Coffee to the podcast independent.

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

When sixteen-year-old Kirsten de Klerk was diagnosed with type 1 diabetes, she asked how long she’d have to live like this. Her doctor replied, “Every day for the rest of your life.”

Years later, that sentence became the fuel for change.

Sign the CGM Access Petition: In less than one-minute, you can change global access to CGM forever.

In this episode, John Pemberton talks with Kirsten about her journey from diabetes burnout to national advocacy, and how her work is now shaping a CGM Access Blueprint for South Africa — a model that could influence global policy.

Episode 22: show notes and links and consider buying the GNL a Coffee to the podcast independent.

They discuss:

  • The emotional toll of diabetes burnout and the power of community.
  • How the #LetterToMyDiabetes movement sparked a nationwide campaign.
  • The reality of access inequality — 85 % of South Africans rely on public healthcare with only a few test strips a day.
  • The creation of SA Diabetes Advocacy, gathering 14 000+ petition signatures for CGM funding.
  • Why access without accuracy is false progress — and how unregulated devices put people at risk.

Kirsten and John explore what happens when lived experience meets evidence, and how persistence — not privilege — drives real change.

Together they outline three truths that every policymaker, clinician, and person with diabetes should understand:

  1. Not all CGMs are created equally.
    Some systems are clinically validated for insulin dosing; others are not. Price competition must not compromise safety.
  2. Inaccuracy harms you now.
    When CGMs fail to detect highs or lows, real people are put at immediate risk.
  3. Inaccuracy harms you later.
    CGMs that systematically under- or over-report glucose create false reassurance — “70% time-in-range on one device might be 60% on another.”

Sign the CGM Access Petition: In less than one-minute, you can change global access to CGM forever.

Links & Resources:
🌍 Sign the CGM Access Petition (South Africa)

📊 DSN Forum UK – CGM Comparison Chart

🔬 FIND Diagnostics – CGM Accuracy Factsheet

📘 GNL FAQ – CGM Regulation & Comparator Bias

📱 Follow Kirsten → @everydayisdiabetesday
| @sadiabetesadvocacy

🎧 Listen, learn, and share.
The CGM Access Blueprint begins in South Africa — but its lessons apply everywhere.

Episode 22: show notes and links and consider buying the GNL a Coffee to the podcast independent.

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18042535 Sat, 25 Oct 2025 05:00:00 +0100 3448 22 full false 21 — Partha Kar’s SPARK: Transforming diabetes care using his “Five-to-Drive-Change” 21 — Partha Kar’s SPARK: Transforming diabetes care using his “Five-to-Drive-Change” Suggest guests or get in contact

Professor Partha Kar joins The Glucose Never Lies® Podcast to unpack how the UK moved from research to reality in continuous glucose monitoring (CGM) and hybrid closed-loop systems (AID) — and how the same approach can be applied to any challenge in life or leadership.

Through openness, accountability, and courage, Partha helped create one of the fastest national tech adoptions in healthcare history. At the centre of that journey sits a practical philosophy anyone can use: the S-P-A-R-K Mindset, his Five-to-Drive-Change Framework.

It’s not just about diabetes care — it’s about how you make things happen.

Get the Full show notes and SPARK download

Help the GNL Podcast reman independent by buying the GNL a Coffee

Partha Kar on what matters:

  • Implementation is where science becomes real
  • Social media can be a listening system and an accountability engine.
  • Accountability ≠ blame — transparency builds trust.
  • Equity starts with measuring bias and publishing it.
  • Language and leadership shape safety.
  • Every change starts with a SPARK.


The S-P-A-R-K Mindset — Five-to-Drive-Change Framework

S – Start small, prove it locally
Change begins in your patch. Pilot, test, measure. Evidence beats opinion.

P – Put your skin in the game
If you believe in it, stand behind it. Take the risk, own the outcome.

A – Accountability, not blame
Use data to shine a light — RAG ratings, heat maps — but keep language neutral. Data should nudge, not shame.

R – Reveal through listening
True leadership starts with the community. Listen first; understand before you act.

K – Keep language human
Words shape behaviour. Talk with people, not at them. Better language builds safer systems.

Chapters

·        00:00 The CGM Journey: From Science to Street

·        04:15 Harnessing Social Media for Change

·        09:19 Accountability Without Blame

·        14:29 Implementation Science in Action

·        19:59 The Future of Diabetes Care

·        20:54 Seeing Bias in the Data

·        23:41 Paediatric Equality — Closing the Gap

·        25:10 Peer Learning from Sweden

·        28:00 Physician Associates — Safety and Scope

·        31:45 Patient Safety and Accuracy in Tech

·        35:35 Skin in the Game — Leadership With Consequences

·        37:57 SPARK Recap — Five-to-Drive Framework

Get the Full show notes and SPARK download

Help the GNL Podcast reman independent by buying the GNL a Coffee

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Professor Partha Kar joins The Glucose Never Lies® Podcast to unpack how the UK moved from research to reality in continuous glucose monitoring (CGM) and hybrid closed-loop systems (AID) — and how the same approach can be applied to any challenge in life or leadership.

Through openness, accountability, and courage, Partha helped create one of the fastest national tech adoptions in healthcare history. At the centre of that journey sits a practical philosophy anyone can use: the S-P-A-R-K Mindset, his Five-to-Drive-Change Framework.

It’s not just about diabetes care — it’s about how you make things happen.

Get the Full show notes and SPARK download

Help the GNL Podcast reman independent by buying the GNL a Coffee

Partha Kar on what matters:

  • Implementation is where science becomes real
  • Social media can be a listening system and an accountability engine.
  • Accountability ≠ blame — transparency builds trust.
  • Equity starts with measuring bias and publishing it.
  • Language and leadership shape safety.
  • Every change starts with a SPARK.


The S-P-A-R-K Mindset — Five-to-Drive-Change Framework

S – Start small, prove it locally
Change begins in your patch. Pilot, test, measure. Evidence beats opinion.

P – Put your skin in the game
If you believe in it, stand behind it. Take the risk, own the outcome.

A – Accountability, not blame
Use data to shine a light — RAG ratings, heat maps — but keep language neutral. Data should nudge, not shame.

R – Reveal through listening
True leadership starts with the community. Listen first; understand before you act.

K – Keep language human
Words shape behaviour. Talk with people, not at them. Better language builds safer systems.

Chapters

·        00:00 The CGM Journey: From Science to Street

·        04:15 Harnessing Social Media for Change

·        09:19 Accountability Without Blame

·        14:29 Implementation Science in Action

·        19:59 The Future of Diabetes Care

·        20:54 Seeing Bias in the Data

·        23:41 Paediatric Equality — Closing the Gap

·        25:10 Peer Learning from Sweden

·        28:00 Physician Associates — Safety and Scope

·        31:45 Patient Safety and Accuracy in Tech

·        35:35 Skin in the Game — Leadership With Consequences

·        37:57 SPARK Recap — Five-to-Drive Framework

Get the Full show notes and SPARK download

Help the GNL Podcast reman independent by buying the GNL a Coffee

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-18035631 Sun, 19 Oct 2025 08:00:00 +0100 2599 21 full false 20 — Standardization of Testing CGM Performance: The Nuts and Bolts with Stefan Pleus of the IFCC 20 — Standardization of Testing CGM Performance: The Nuts and Bolts with Stefan Pleus of the IFCC Suggest guests or get in contact

Episode 20 — Standardization of Testing CGM Performance: The Nuts and Bolts

With Dr. Stefan Pleus (Institut für Diabetes-Technologie, Universität Ulm; Chair of the IFCC Working Group on CGM).

Full show notes and FAQ, and consider buying me a Coffee to keep pumping.

In this episode, we go deep into the future of continuous glucose monitoring (CGM) standards. Dr. Pleus explains why the FDA iCGM framework (2018) is no longer enough, what a robust international standard would look like, and why ISO standardisation by 2030 is essential if CGM is to:

  • Be a reliable basis for insulin dosing
  • Act as a trusted comparator in clinical trials
  • Enable screening and early diagnosis of type 1 diabetes
  • Provide consistency across devices for people with diabetes

Key insights from Stefan Pleus:

  • Study design matters: if you avoid rapid glucose changes, results look good — but that’s not real life.
  • Stress-testing requires minimum data in low, high, and rapid-change zones.
  • Every comparator has bias: retrospective correction is essential to align results across manufacturers.
  • With better study designs, today’s systems may appear less accurate — but only because we’re finally testing them properly.
  • Global alignment between FDA and Europe is needed; without it, innovation risks stalling.

Why this matters:


 Without standardisation, insulin dosing, clinical trials, and diagnostics will remain inconsistent across devices. The 2030 opportunity is a global, reproducible framework that ensures fairness for users, clarity for clinicians, and valid results for researchers.

Full show notes and FAQ, and consider buying me a Coffee to keep pumping.

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Episode 20 — Standardization of Testing CGM Performance: The Nuts and Bolts

With Dr. Stefan Pleus (Institut für Diabetes-Technologie, Universität Ulm; Chair of the IFCC Working Group on CGM).

Full show notes and FAQ, and consider buying me a Coffee to keep pumping.

In this episode, we go deep into the future of continuous glucose monitoring (CGM) standards. Dr. Pleus explains why the FDA iCGM framework (2018) is no longer enough, what a robust international standard would look like, and why ISO standardisation by 2030 is essential if CGM is to:

  • Be a reliable basis for insulin dosing
  • Act as a trusted comparator in clinical trials
  • Enable screening and early diagnosis of type 1 diabetes
  • Provide consistency across devices for people with diabetes

Key insights from Stefan Pleus:

  • Study design matters: if you avoid rapid glucose changes, results look good — but that’s not real life.
  • Stress-testing requires minimum data in low, high, and rapid-change zones.
  • Every comparator has bias: retrospective correction is essential to align results across manufacturers.
  • With better study designs, today’s systems may appear less accurate — but only because we’re finally testing them properly.
  • Global alignment between FDA and Europe is needed; without it, innovation risks stalling.

Why this matters:


 Without standardisation, insulin dosing, clinical trials, and diagnostics will remain inconsistent across devices. The 2030 opportunity is a global, reproducible framework that ensures fairness for users, clarity for clinicians, and valid results for researchers.

Full show notes and FAQ, and consider buying me a Coffee to keep pumping.

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-17922811 Tue, 30 Sep 2025 04:00:00 +0100 3481 20 full false 19 – iCGM vs eCGM vs Standardisation by the IFCC: CGM Regulation with Dr. Guido Freckmann 19 – iCGM vs eCGM vs Standardisation by the IFCC: CGM Regulation with Dr. Guido Freckmann Suggest guests or get in contact

19 – iCGM vs eCGM vs Standardisation by the IFCC: CGM Regulation with Dr. Guido Freckmann

Full show notes and FAQ, and consider buying me a Coffee to keep pumping

Continuous glucose monitoring (CGM) has transformed diabetes care — but how do we know which systems are accurate, safe, and truly comparable? 

In this episode, John Pemberton is joined by Dr. Guido Freckmann (Institute of Diabetes Technology, Ulm; former chair of the IFCC CGM Working Group). Together they unpack: 

  • Why CE marking in Europe is not a quality standard
  • How the FDA’s iCGM framework (2018) was groundbreaking, but has limitations in study design
  • Why the proposed eCGM model for Europe risks monopolising the market without fixing accuracy problems
  • The IFCC’s roadmap towards a full ISO standard for CGM – robust, reproducible, and aligned with clinical reality

Full Show notes and FAQ, and consider buying me a Coffee to keep pumping

Key Themes & Watch-Outs

🔹 CE Mark ≠ Quality Standard

  • CE marking is a regulatory pathway, not a guarantee of performance.
  • Manufacturers can submit selective data, and the results are not public.

🔹 ICGM (2018): A Step Forward, But Outdated

  • FDA iCGM rules set minimum standards, but study design criteria were vague.
  • Devices can appear accurate by avoiding stressful glucose swings.

🔹 Why Standardisation Matters

  • Standardisation would define not just performance metrics but also how studies are run.
  • It would align CGM systems to the same comparator (capillary or venous) and reduce therapy discrepancies.

🔹 Capillary vs Venous Debate

  • Capillary glucose reflects what people actually test and what their bodies are exposed to.
  • Venous alignment risks giving a “false reassurance” of being in range.
  • An agreement is needed: whichever is chosen must be standardised, with bias correction.

🔹 Clinical Impact

  • Different CGMs can give the same time-in-range but very different HbA1c and complication risk.
  • That undermines trust, confuses therapy adjustments, and makes clinical trial endpoints unreliable.

🔹 Looking Ahead

  • CGM standardisation is in motion, but likely won’t be implemented before 2030.
  • Until then, clinicians and people with diabetes need to scrutinise study design and remain critical of performance claims.

 
Quotes from the Episode

“CE marking is not a quality standard. You have to dig into study design — and that’s not practical for the average person with diabetes or most clinicians.” – John Pemberton

“CGM systems often perform worse at high rates of change than at stable glucose levels. That’s why stress-testing is vital.” – Dr. Guido Freckmann

“Different CGM systems can give the same time-in-range but very different HbA1c and complication risks. That’s unacceptable.” – John Pemberton

“Manufacturers can design studies to get good results by avoiding rapid glucose swings. Without rules, accuracy is only on paper.” – Dr. Guido Freckmann

Full Show notes and FAQ, and consider buying me a Coffee to keep pumping


 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The G

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

19 – iCGM vs eCGM vs Standardisation by the IFCC: CGM Regulation with Dr. Guido Freckmann

Full show notes and FAQ, and consider buying me a Coffee to keep pumping

Continuous glucose monitoring (CGM) has transformed diabetes care — but how do we know which systems are accurate, safe, and truly comparable? 

In this episode, John Pemberton is joined by Dr. Guido Freckmann (Institute of Diabetes Technology, Ulm; former chair of the IFCC CGM Working Group). Together they unpack: 

  • Why CE marking in Europe is not a quality standard
  • How the FDA’s iCGM framework (2018) was groundbreaking, but has limitations in study design
  • Why the proposed eCGM model for Europe risks monopolising the market without fixing accuracy problems
  • The IFCC’s roadmap towards a full ISO standard for CGM – robust, reproducible, and aligned with clinical reality

Full Show notes and FAQ, and consider buying me a Coffee to keep pumping

Key Themes & Watch-Outs

🔹 CE Mark ≠ Quality Standard

  • CE marking is a regulatory pathway, not a guarantee of performance.
  • Manufacturers can submit selective data, and the results are not public.

🔹 ICGM (2018): A Step Forward, But Outdated

  • FDA iCGM rules set minimum standards, but study design criteria were vague.
  • Devices can appear accurate by avoiding stressful glucose swings.

🔹 Why Standardisation Matters

  • Standardisation would define not just performance metrics but also how studies are run.
  • It would align CGM systems to the same comparator (capillary or venous) and reduce therapy discrepancies.

🔹 Capillary vs Venous Debate

  • Capillary glucose reflects what people actually test and what their bodies are exposed to.
  • Venous alignment risks giving a “false reassurance” of being in range.
  • An agreement is needed: whichever is chosen must be standardised, with bias correction.

🔹 Clinical Impact

  • Different CGMs can give the same time-in-range but very different HbA1c and complication risk.
  • That undermines trust, confuses therapy adjustments, and makes clinical trial endpoints unreliable.

🔹 Looking Ahead

  • CGM standardisation is in motion, but likely won’t be implemented before 2030.
  • Until then, clinicians and people with diabetes need to scrutinise study design and remain critical of performance claims.

 
Quotes from the Episode

“CE marking is not a quality standard. You have to dig into study design — and that’s not practical for the average person with diabetes or most clinicians.” – John Pemberton

“CGM systems often perform worse at high rates of change than at stable glucose levels. That’s why stress-testing is vital.” – Dr. Guido Freckmann

“Different CGM systems can give the same time-in-range but very different HbA1c and complication risks. That’s unacceptable.” – John Pemberton

“Manufacturers can design studies to get good results by avoiding rapid glucose swings. Without rules, accuracy is only on paper.” – Dr. Guido Freckmann

Full Show notes and FAQ, and consider buying me a Coffee to keep pumping


 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The G

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-17922620 Tue, 30 Sep 2025 04:00:00 +0100 1731 19 full false 18 — Physical Activity vs Exercise: the Before–During–After Playbook with Prof. Othmar Moser 18 — Physical Activity vs Exercise: the Before–During–After Playbook with Prof. Othmar Moser Suggest guests or get in contact

What’s the difference between physical activity and exercise when you live with type 1 diabetes? And why does it matter? 

Full show notes & transcript: Episode 18 page 

In this episode, I’m joined by Prof. Othmar Moser, exercise physiologist, guideline author, and fellow person with type 1, to break down: 

  • Why 10 minutes of activity after meals is the easiest, most powerful place to start.
  • The 20/20 and 40/40 rules — how 20 minutes of light movement can drop glucose by 20–40 mg/dL (1–2 mmol/L).
  • How CGM feedback makes activity tangible and motivating.
  • The Before–During–After playbook for structured exercise:
    • Before: meal timing, prandial reductions, AID temp targets, basal adjustments.
    • During: safe glucose range, 3–20 g carb top-ups, when to fingerstick.
    • After: the first hour of hypo risk, late-night dips, protein strategy, and therapy-specific caveats (AID vs Pump vs MDI).


Full show notes & transcript: Episode 10 page

Explore the FAQ resource with all the key questions and diagrams: FAQ — T1D Exercise & Activity

Support the podcast
If this episode helps you or your clinic, you can fuel more episodes by buying me a coffee ☕ → https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

About The Glucose Never Lies® Podcast
This podcast translates the latest diabetes science into practical, real-world steps. Honest conversations with the world’s leading researchers, mixed with the lived experience of people with type 1 diabetes.

Disclaimer:
This podcast is for informational purposes only and does not replace medical advice. Always consult your healthcare professional before changing therapy.

© The Glucose Never Lies® Ltd
 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

What’s the difference between physical activity and exercise when you live with type 1 diabetes? And why does it matter? 

Full show notes & transcript: Episode 18 page 

In this episode, I’m joined by Prof. Othmar Moser, exercise physiologist, guideline author, and fellow person with type 1, to break down: 

  • Why 10 minutes of activity after meals is the easiest, most powerful place to start.
  • The 20/20 and 40/40 rules — how 20 minutes of light movement can drop glucose by 20–40 mg/dL (1–2 mmol/L).
  • How CGM feedback makes activity tangible and motivating.
  • The Before–During–After playbook for structured exercise:
    • Before: meal timing, prandial reductions, AID temp targets, basal adjustments.
    • During: safe glucose range, 3–20 g carb top-ups, when to fingerstick.
    • After: the first hour of hypo risk, late-night dips, protein strategy, and therapy-specific caveats (AID vs Pump vs MDI).


Full show notes & transcript: Episode 10 page

Explore the FAQ resource with all the key questions and diagrams: FAQ — T1D Exercise & Activity

Support the podcast
If this episode helps you or your clinic, you can fuel more episodes by buying me a coffee ☕ → https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

About The Glucose Never Lies® Podcast
This podcast translates the latest diabetes science into practical, real-world steps. Honest conversations with the world’s leading researchers, mixed with the lived experience of people with type 1 diabetes.

Disclaimer:
This podcast is for informational purposes only and does not replace medical advice. Always consult your healthcare professional before changing therapy.

© The Glucose Never Lies® Ltd
 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-17897391 Wed, 24 Sep 2025 11:00:00 +0100 3755 18 full false 17 – GLP-1 in Type 1 Diabetes: beyond weight loss, towards metabolic therapy? 17 – GLP-1 in Type 1 Diabetes: beyond weight loss, towards metabolic therapy? Suggest guests or get in contact

Episode 17 — GLP-1 in Type 1 Diabetes: Beyond Weight Loss, Towards Metabolic Therapy

 Go to the Podcast page for all the notes, insights, and further reading & listening.

Subscribe to The Glucose Never Lies® and receive the Summary PDF with all the key take-home messages and practical implementation strategies. 

Support The Glucose Never Lies® Podcast
☕ Buy Me a Coffee
💙 Donate


Guest: Professor Viral Shah, MD

  • Professor of Medicine & Director of Diabetes Clinical Research, Center for Diabetes and Metabolic Diseases, IU School of Medicine
  • Author of multiple clinical trials and consensus guidelines on GLP-1 and incretin therapies in type 1 diabetes

In this episode, John Pemberton speaks with Professor Viral Shah, a leading researcher in incretin therapies, about:

  • The unique challenges of type 1 diabetes (insulin resistance, glucagon, weight gain).
  • The evidence for GLP-1s in T1D: up to 30% insulin reduction, weight loss, and improved time in range.
  • Practical guidance for people with type 1 and healthcare professionals: insulin titration, MDI vs pump vs AID, nutrition, and risk–benefit.

Subscribe to The Glucose Never Lies® and receive the Summary PDF with all the key take-home messages and practical implementation strategies. 

Go to the Podcast page for all the notes, insights, and further reading & listening.

Related GNL Resources

  • Overcoming Insulin Resistance in T1D
  • Eight Causes of Insulin Resistance
  • Seven Ways to Combat Insulin Resistance
  • Automated Insulin Delivery Series
  • CGM Series
  • GNL Podcast Episode 14 Overcoming Insulin Resistance

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Episode 17 — GLP-1 in Type 1 Diabetes: Beyond Weight Loss, Towards Metabolic Therapy

 Go to the Podcast page for all the notes, insights, and further reading & listening.

Subscribe to The Glucose Never Lies® and receive the Summary PDF with all the key take-home messages and practical implementation strategies. 

Support The Glucose Never Lies® Podcast
☕ Buy Me a Coffee
💙 Donate


Guest: Professor Viral Shah, MD

  • Professor of Medicine & Director of Diabetes Clinical Research, Center for Diabetes and Metabolic Diseases, IU School of Medicine
  • Author of multiple clinical trials and consensus guidelines on GLP-1 and incretin therapies in type 1 diabetes

In this episode, John Pemberton speaks with Professor Viral Shah, a leading researcher in incretin therapies, about:

  • The unique challenges of type 1 diabetes (insulin resistance, glucagon, weight gain).
  • The evidence for GLP-1s in T1D: up to 30% insulin reduction, weight loss, and improved time in range.
  • Practical guidance for people with type 1 and healthcare professionals: insulin titration, MDI vs pump vs AID, nutrition, and risk–benefit.

Subscribe to The Glucose Never Lies® and receive the Summary PDF with all the key take-home messages and practical implementation strategies. 

Go to the Podcast page for all the notes, insights, and further reading & listening.

Related GNL Resources

  • Overcoming Insulin Resistance in T1D
  • Eight Causes of Insulin Resistance
  • Seven Ways to Combat Insulin Resistance
  • Automated Insulin Delivery Series
  • CGM Series
  • GNL Podcast Episode 14 Overcoming Insulin Resistance

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-17793807 Fri, 12 Sep 2025 09:00:00 +0100 4115 17 full false 16: Diabetes & Driving: Why You Need to Be 5 to Drive 16: Diabetes & Driving: Why You Need to Be 5 to Drive Suggest guests or get in contact

Episode 16 — Diabetes & Driving: Why You Need to Be 5 to Drive


Show summary PDF and full notes here


Support The Glucose Never Lies® Podcast
☕ Buy Me a Coffee
💙 Donate


Guest: Professor Pratik Choudhary (University of Leicester, Leicester Diabetes Centre; Chair, DVLA Medical Advisory Panel on Diabetes)

 

Host: John Pemberton (The Glucose Never Lies® Podcast)


Episode Overview
Driving with type 1 diabetes is not just about safety. It comes with clear legal responsibilities.


We cover:
  • The legal differences between Group 1 (cars, motorcycles ≤3.5 t, ≤8 passengers) and Group 2 (HGV, minibuses, passenger vehicles >3.5 t or >8 passengers).
  • Why the law requires you to be ≥5 mmol/L before driving (“5 to drive”).
  • The 45-minute rule: after treating a hypo, you must wait 45 minutes once you are back above 5 mmol/L.
  • When CGM readings are accepted (Group 1) versus when only finger-prick testing counts (Group 2, currently).
  • The importance of self-declaring severe hypoglycaemia: two daytime events in 12 months means you must report it.
  • Practical tips: keeping your meter’s date/time accurate, carrying a backup meter, and setting CGM low alerts at 5 for long journeys.

Key Takeaways
  • 5 to drive: ≥5.0 mmol/L
  • 4.0–4.9 mmol/L: snack, then drive
  • <4.0 mmol/L: treat → confirm >5.0 → wait 45 minutes once above 5
  • Check every ≤2 hours — each check “expires” like a parking ticket
  • Group 1 drivers: CGM or finger-prick both accepted
  • Group 2 drivers: finger-prick only (until law changes)
  • Severe hypos: two daytime events in 12 months → you must self-declare
  • Responsibility lies with the driver, not your clinician


Resources and Further Reading


Visit The Glucose Never Lies® — Episode 16 to access:


  • DVLA INF294 — Insulin-treated diabetes and driving (official guidance)

  • NHS England guidance on approved blood glucose meters

  • DSN Forum CGM Accuracy Comparison Chart

  • CGM Guides — The Glucose Never Lies®

  • Automated Insulin Delivery Guides — The Glucose Never Lies®

Listen or Watch - 


Click here to access your favourite provider, whether by video or audio



Disclaimer

It does not replace official DVLA guidance (INF294). Rules may change. Always check the latest DVLA information before making decisions about driving.


Prepared by John Pemberton 

Executed by the Legend that is: Professor Pratik Choudhary

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Episode 16 — Diabetes & Driving: Why You Need to Be 5 to Drive


Show summary PDF and full notes here


Support The Glucose Never Lies® Podcast
☕ Buy Me a Coffee
💙 Donate


Guest: Professor Pratik Choudhary (University of Leicester, Leicester Diabetes Centre; Chair, DVLA Medical Advisory Panel on Diabetes)

 

Host: John Pemberton (The Glucose Never Lies® Podcast)


Episode Overview
Driving with type 1 diabetes is not just about safety. It comes with clear legal responsibilities.


We cover:
  • The legal differences between Group 1 (cars, motorcycles ≤3.5 t, ≤8 passengers) and Group 2 (HGV, minibuses, passenger vehicles >3.5 t or >8 passengers).
  • Why the law requires you to be ≥5 mmol/L before driving (“5 to drive”).
  • The 45-minute rule: after treating a hypo, you must wait 45 minutes once you are back above 5 mmol/L.
  • When CGM readings are accepted (Group 1) versus when only finger-prick testing counts (Group 2, currently).
  • The importance of self-declaring severe hypoglycaemia: two daytime events in 12 months means you must report it.
  • Practical tips: keeping your meter’s date/time accurate, carrying a backup meter, and setting CGM low alerts at 5 for long journeys.

Key Takeaways
  • 5 to drive: ≥5.0 mmol/L
  • 4.0–4.9 mmol/L: snack, then drive
  • <4.0 mmol/L: treat → confirm >5.0 → wait 45 minutes once above 5
  • Check every ≤2 hours — each check “expires” like a parking ticket
  • Group 1 drivers: CGM or finger-prick both accepted
  • Group 2 drivers: finger-prick only (until law changes)
  • Severe hypos: two daytime events in 12 months → you must self-declare
  • Responsibility lies with the driver, not your clinician


Resources and Further Reading


Visit The Glucose Never Lies® — Episode 16 to access:


  • DVLA INF294 — Insulin-treated diabetes and driving (official guidance)

  • NHS England guidance on approved blood glucose meters

  • DSN Forum CGM Accuracy Comparison Chart

  • CGM Guides — The Glucose Never Lies®

  • Automated Insulin Delivery Guides — The Glucose Never Lies®

Listen or Watch - 


Click here to access your favourite provider, whether by video or audio



Disclaimer

It does not replace official DVLA guidance (INF294). Rules may change. Always check the latest DVLA information before making decisions about driving.


Prepared by John Pemberton 

Executed by the Legend that is: Professor Pratik Choudhary

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-17789201 Sun, 07 Sep 2025 04:00:00 +0100 3298 16 full false 15: C-Peptide - What type of type 1 diabetes do you have? 15: C-Peptide - What type of type 1 diabetes do you have? Suggest guests or get in contact

    

Hosted by diabetes dietitian John Pemberton, this show blends science and real-life experience to make managing type 1 diabetes easier, clearer, and more human. Smart insights, practical tips, and honest conversations await. 

It's all about C-Peptide and what it means for people living with T1D! 

 
🕒 [00:09] Think all T1D is the same? Think again.

🕒 [02:14] Some people really do have it harder — and “brittle diabetes” might be real.

🕒 [04:37] Enter C-peptide: a marker of how much insulin your body still makes.

🕒 [06:10] Know your number:
• High: >200 pmol/L
• Intermediate: 30–200
• Low: <30

🕒 [09:11] Diagnosed young? You likely have lower C-peptide. John, diagnosed at 27, still has 220 after 10 years.

🕒 [10:20] High C-peptide = better time-in-range, fewer hypos, fewer complications.

🕒 [13:10] Why? More portal insulin + less glucagon = smoother control.

🕒 [14:01] Use your C-peptide to prioritise tech and tailor therapy (GLP-1s, HCL systems, nutrition).

🕒 [17:55] Most of all—be kind to yourself. It’s not weakness. It’s biology.
 
 

Key resources 

Episode 14: Insulin Resistance and T1D

C-Peptide full article – click here 


 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

    

Hosted by diabetes dietitian John Pemberton, this show blends science and real-life experience to make managing type 1 diabetes easier, clearer, and more human. Smart insights, practical tips, and honest conversations await. 

It's all about C-Peptide and what it means for people living with T1D! 

 
🕒 [00:09] Think all T1D is the same? Think again.

🕒 [02:14] Some people really do have it harder — and “brittle diabetes” might be real.

🕒 [04:37] Enter C-peptide: a marker of how much insulin your body still makes.

🕒 [06:10] Know your number:
• High: >200 pmol/L
• Intermediate: 30–200
• Low: <30

🕒 [09:11] Diagnosed young? You likely have lower C-peptide. John, diagnosed at 27, still has 220 after 10 years.

🕒 [10:20] High C-peptide = better time-in-range, fewer hypos, fewer complications.

🕒 [13:10] Why? More portal insulin + less glucagon = smoother control.

🕒 [14:01] Use your C-peptide to prioritise tech and tailor therapy (GLP-1s, HCL systems, nutrition).

🕒 [17:55] Most of all—be kind to yourself. It’s not weakness. It’s biology.
 
 

Key resources 

Episode 14: Insulin Resistance and T1D

C-Peptide full article – click here 


 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-17593379 Thu, 31 Jul 2025 14:00:00 +0100 1400 15 full false 14: Overcoming Insulin Resistance in Type 1 Diabetes 14: Overcoming Insulin Resistance in Type 1 Diabetes Suggest guests or get in contact

In this deep-dive episode, John Pemberton explores the misunderstood world of insulin resistance in people with type 1 diabetes. Drawing on years of personal experience, clinical expertise, and the latest research, he breaks down why insulin resistance matters—even in a condition defined by insulin deficiency.

Click here for the detailed 3-part write up

The episode walks through the 'Ominous Octet', eight mechanisms that drive insulin resistance, and explains how they impact blood glucose control, weight management, and long-term health. More importantly, it offers practical strategies to reduce total daily insulin dose through lifestyle changes, activity, nutrition, and pharmacological options.

Whether you're living with T1D, supporting someone who is, or simply want to better understand the complex interplay between insulin and the body, this episode provides clarity and direction.

Takeaways:

  • People with T1D often require more insulin due to lack of portal delivery and higher peripheral levels
  • Insulin resistance occurs in the liver, muscle, brain, kidneys, gut, and fat tissue
  • Measuring units per kilogram is a useful proxy for insulin sensitivity
  • Activity is the most powerful modifiable factor for improving insulin sensitivity
  • Weight loss, high-protein diets, and reduced saturated fat intake all help reduce resistance
  • GLP-1 and dual agonists (e.g., tirzepatide) show promise for T1D, but are not yet widely approved
  • SGLT2 inhibitors and pioglitazone offer targeted benefits but must be used with care
  • A multifaceted approach is often needed to lower insulin needs and support health

Chapters:

00:00 - 02:10 | Introduction

  • John Pemberton welcomes listeners to Episode 14.
  • Shares his background: living with T1D, creating the Glucose Never Lies Education Programme, and motivation from personal and family experiences.
  • Introduces co-host Louise (not present in this episode).
  • Outlines the episode focus: insulin resistance in type 1 diabetes.

02:10 - 04:35 | Why Insulin Resistance Matters in T1D

04:35 - 06:50 | The Metabolic Disadvantage in T1D

  • Describes differences in insulin delivery: endogenous (via portal vein in non-diabetics) vs. exogenous (subcutaneous in T1D).
  • Explains how peripheral insulin levels are 4–8x higher in T1D, contributing to insulin resistance.

06:50 - 09:15 | The Ominous Octet

  • Introduces eight mechanisms of insulin resistance (based on Dr. Ralph DeFronzo’s work): 
    1. Liver insulin resistance
    2. Muscle insulin resistance
    3. Beta-cell dysfunction
    4. Hyperglucagonemia
    5. Brain insulin resistance
    6. Gut hormone dysfunction
    7. Fat cell dysfunction
    8. Kidney (renal) insulin resistance

09:15 - 11:30 | Measuring Insulin Resistance

  • Euglycemic clamp = gold standard (not used in T1D).
  • Use total daily insulin (TDI) per kilogram as a practical metric.
  • Defines ranges:
    • <0.4 units/kg = insulin sensitive
    • 0.5–0.7 = mild insulin resistance
    • 0.7–1.0 = moderate
    • 1.0 = high insuli

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

In this deep-dive episode, John Pemberton explores the misunderstood world of insulin resistance in people with type 1 diabetes. Drawing on years of personal experience, clinical expertise, and the latest research, he breaks down why insulin resistance matters—even in a condition defined by insulin deficiency.

Click here for the detailed 3-part write up

The episode walks through the 'Ominous Octet', eight mechanisms that drive insulin resistance, and explains how they impact blood glucose control, weight management, and long-term health. More importantly, it offers practical strategies to reduce total daily insulin dose through lifestyle changes, activity, nutrition, and pharmacological options.

Whether you're living with T1D, supporting someone who is, or simply want to better understand the complex interplay between insulin and the body, this episode provides clarity and direction.

Takeaways:

  • People with T1D often require more insulin due to lack of portal delivery and higher peripheral levels
  • Insulin resistance occurs in the liver, muscle, brain, kidneys, gut, and fat tissue
  • Measuring units per kilogram is a useful proxy for insulin sensitivity
  • Activity is the most powerful modifiable factor for improving insulin sensitivity
  • Weight loss, high-protein diets, and reduced saturated fat intake all help reduce resistance
  • GLP-1 and dual agonists (e.g., tirzepatide) show promise for T1D, but are not yet widely approved
  • SGLT2 inhibitors and pioglitazone offer targeted benefits but must be used with care
  • A multifaceted approach is often needed to lower insulin needs and support health

Chapters:

00:00 - 02:10 | Introduction

  • John Pemberton welcomes listeners to Episode 14.
  • Shares his background: living with T1D, creating the Glucose Never Lies Education Programme, and motivation from personal and family experiences.
  • Introduces co-host Louise (not present in this episode).
  • Outlines the episode focus: insulin resistance in type 1 diabetes.

02:10 - 04:35 | Why Insulin Resistance Matters in T1D

04:35 - 06:50 | The Metabolic Disadvantage in T1D

  • Describes differences in insulin delivery: endogenous (via portal vein in non-diabetics) vs. exogenous (subcutaneous in T1D).
  • Explains how peripheral insulin levels are 4–8x higher in T1D, contributing to insulin resistance.

06:50 - 09:15 | The Ominous Octet

  • Introduces eight mechanisms of insulin resistance (based on Dr. Ralph DeFronzo’s work): 
    1. Liver insulin resistance
    2. Muscle insulin resistance
    3. Beta-cell dysfunction
    4. Hyperglucagonemia
    5. Brain insulin resistance
    6. Gut hormone dysfunction
    7. Fat cell dysfunction
    8. Kidney (renal) insulin resistance

09:15 - 11:30 | Measuring Insulin Resistance

  • Euglycemic clamp = gold standard (not used in T1D).
  • Use total daily insulin (TDI) per kilogram as a practical metric.
  • Defines ranges:
    • <0.4 units/kg = insulin sensitive
    • 0.5–0.7 = mild insulin resistance
    • 0.7–1.0 = moderate
    • 1.0 = high insuli

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-17569446 Sun, 27 Jul 2025 14:00:00 +0100 2782 14 full false 12: CGM Functionality (Part 3): The Bells and Whistles 12: CGM Functionality (Part 3): The Bells and Whistles Suggest guests or get in contact

In this episode of the Glucose Never Lies podcast, hosts John Pemberton and Louise discuss the intricacies of diabetes management, focusing on continuous glucose monitoring (CGM) systems. They explore various CGM features, including calibration, alarms, and connectivity with automated insulin delivery (AID) systems. The conversation emphasizes the importance of understanding individual needs when selecting a CGM, as well as the role of technology in enhancing diabetes care. The hosts also provide insights into the latest advancements in CGM technology and offer resources for further education.

Takeaways

  • Continuous glucose monitors (CGMs) have evolved to include factory calibration.
  • Optional calibration can be beneficial but requires accurate blood glucose meters.
  • Alarm fatigue can hinder effective diabetes management.
  • The Freestyle Libre is noted for its small size and long wear time.
  • Dexcom products offer extensive connectivity with AID systems.
  • Understanding individual needs is crucial when selecting a CGM.
  • AI-driven forecasts in CGMs can enhance decision-making for users.
  • Education and support are vital for effective diabetes management.
  • Resources like the DSM Forum provide valuable information for diabetes care.

Chapters

00:00
Introduction to Diabetes Management

02:14
Continuous Glucose Monitoring (CGM) Overview

13:09
Understanding CGM Features and Alarms

21:27
Evaluating CGM Size and Connectivity

27:21
Final Thoughts and Resources

Key Resources:

CGM Series: CGM: The Bells and Whistles

Chart for CGM Devices (From May 2025): DSN Forum

Tim Street @ Diabettech

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

In this episode of the Glucose Never Lies podcast, hosts John Pemberton and Louise discuss the intricacies of diabetes management, focusing on continuous glucose monitoring (CGM) systems. They explore various CGM features, including calibration, alarms, and connectivity with automated insulin delivery (AID) systems. The conversation emphasizes the importance of understanding individual needs when selecting a CGM, as well as the role of technology in enhancing diabetes care. The hosts also provide insights into the latest advancements in CGM technology and offer resources for further education.

Takeaways

  • Continuous glucose monitors (CGMs) have evolved to include factory calibration.
  • Optional calibration can be beneficial but requires accurate blood glucose meters.
  • Alarm fatigue can hinder effective diabetes management.
  • The Freestyle Libre is noted for its small size and long wear time.
  • Dexcom products offer extensive connectivity with AID systems.
  • Understanding individual needs is crucial when selecting a CGM.
  • AI-driven forecasts in CGMs can enhance decision-making for users.
  • Education and support are vital for effective diabetes management.
  • Resources like the DSM Forum provide valuable information for diabetes care.

Chapters

00:00
Introduction to Diabetes Management

02:14
Continuous Glucose Monitoring (CGM) Overview

13:09
Understanding CGM Features and Alarms

21:27
Evaluating CGM Size and Connectivity

27:21
Final Thoughts and Resources

Key Resources:

CGM Series: CGM: The Bells and Whistles

Chart for CGM Devices (From May 2025): DSN Forum

Tim Street @ Diabettech

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-16952429 Fri, 09 May 2025 13:00:00 +0100 1821 full false 11: CGM Accuracy (Part 2): Understanding MARD, 20/20, 40/40, and Error Grids. 11: CGM Accuracy (Part 2): Understanding MARD, 20/20, 40/40, and Error Grids. Suggest guests or get in contact

In this episode of the Glucose Never Lies podcast, hosts John Pemberton and Louise discuss the intricacies of diabetes management, focusing on continuous glucose monitoring (CGM) systems. They explore the importance of CGM accuracy, the standards set by regulatory bodies, and the significance of testing conditions in evaluating these devices. The conversation delves into various metrics used to assess CGM performance, including MARD, 20/20 and 40/40 agreement rates, and highlights the need for robust testing against capillary glucose to ensure effective diabetes management. The episode emphasises the importance of transparency in CGM studies and the future directions for standardizing testing protocols.

takeaways

  • CGM systems are crucial for real-time glucose monitoring.
  • FDA standards are currently the highest for CGM performance.
  • CE marking does not guarantee device accuracy or reliability.
  • Testing conditions significantly impact CGM accuracy results.
  • The 20/20 standard indicates no risk for insulin dosing decisions.
  • The 40/40 metric identifies high-risk readings in CGM data.
  • Robust testing against capillary glucose is essential for accuracy.
  • Standardization in CGM testing is needed for better diabetes management.
  • Transparency in CGM studies is vital for healthcare professionals and patients.

00:00
Introduction to Diabetes Management and Podcast Goals

02:07
Understanding Continuous Glucose Monitoring (CGM) Systems

06:08
Evaluating CGM Accuracy and Performance Standards

10:09
The Importance of Testing Conditions in CGM Studies

14:13
Metrics for Assessing CGM Accuracy

18:03
Comparing CGM Systems Against Capillary Glucose

22:02
Future Directions for CGM Testing and Standards

Key Resources

CGM Series: Assessing CGM Accuracy Performance

Chart for CGM Devices (From May 2025): DSN Forum

Tim Street @ Diabettech

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

In this episode of the Glucose Never Lies podcast, hosts John Pemberton and Louise discuss the intricacies of diabetes management, focusing on continuous glucose monitoring (CGM) systems. They explore the importance of CGM accuracy, the standards set by regulatory bodies, and the significance of testing conditions in evaluating these devices. The conversation delves into various metrics used to assess CGM performance, including MARD, 20/20 and 40/40 agreement rates, and highlights the need for robust testing against capillary glucose to ensure effective diabetes management. The episode emphasises the importance of transparency in CGM studies and the future directions for standardizing testing protocols.

takeaways

  • CGM systems are crucial for real-time glucose monitoring.
  • FDA standards are currently the highest for CGM performance.
  • CE marking does not guarantee device accuracy or reliability.
  • Testing conditions significantly impact CGM accuracy results.
  • The 20/20 standard indicates no risk for insulin dosing decisions.
  • The 40/40 metric identifies high-risk readings in CGM data.
  • Robust testing against capillary glucose is essential for accuracy.
  • Standardization in CGM testing is needed for better diabetes management.
  • Transparency in CGM studies is vital for healthcare professionals and patients.

00:00
Introduction to Diabetes Management and Podcast Goals

02:07
Understanding Continuous Glucose Monitoring (CGM) Systems

06:08
Evaluating CGM Accuracy and Performance Standards

10:09
The Importance of Testing Conditions in CGM Studies

14:13
Metrics for Assessing CGM Accuracy

18:03
Comparing CGM Systems Against Capillary Glucose

22:02
Future Directions for CGM Testing and Standards

Key Resources

CGM Series: Assessing CGM Accuracy Performance

Chart for CGM Devices (From May 2025): DSN Forum

Tim Street @ Diabettech

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-16952421 Thu, 10 Apr 2025 16:00:00 +0100 1897 full false 10: CGM Accuracy (Part 1) "Study Design First, Performance After" 10: CGM Accuracy (Part 1) "Study Design First, Performance After" Suggest guests or get in contact

In this episode of the Glucose Never Lies podcast, hosts John Pemberton and Louise delve into the intricacies of diabetes management, focusing on continuous glucose monitoring (CGM) systems. They discuss the importance of understanding CGM accuracy, the significance of study design in evaluating sensor performance, and the key questions to ask when assessing the reliability of these devices. The conversation emphasises the need for robust testing conditions to ensure that CGMs provide accurate readings for insulin dosing decisions. The hosts also highlight the ongoing efforts towards standardisation in CGM technology to improve diabetes care.

Takeaways

  • Continuous glucose monitors (CGMs) are crucial for insulin dosing decisions.
  • Understanding study design is essential for evaluating CGM accuracy.
  • Not all CGMs are created equal; performance varies significantly.
  • Key questions to assess CGM accuracy include the study population and testing conditions.
  • Robust testing conditions are necessary for reliable sensor performance.
  • The importance of peer-reviewed data in evaluating CGM accuracy.
  • Standardization in CGM technology is on the horizon.
  • Healthcare professionals should be knowledgeable about CGM performance.
  • A downloadable chart will be available to help users assess CGM options.

Chapters

00:00
Introduction to Diabetes Management

02:14
Understanding Continuous Glucose Monitoring (CGM)

05:11
Accuracy of Continuous Glucose Monitors

10:13
Evaluating Sensor Performance

15:45
Key Questions for Sensor Accuracy

20:31
Moving Towards Standardization in CGM

25:03
Summary and Next Steps


Key Resources

CGM Series: Understanding Risk Before Performance

Chart for CGM Devices (From May 2025): DSN Forum

Tim Street @ Diabettech


 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

In this episode of the Glucose Never Lies podcast, hosts John Pemberton and Louise delve into the intricacies of diabetes management, focusing on continuous glucose monitoring (CGM) systems. They discuss the importance of understanding CGM accuracy, the significance of study design in evaluating sensor performance, and the key questions to ask when assessing the reliability of these devices. The conversation emphasises the need for robust testing conditions to ensure that CGMs provide accurate readings for insulin dosing decisions. The hosts also highlight the ongoing efforts towards standardisation in CGM technology to improve diabetes care.

Takeaways

  • Continuous glucose monitors (CGMs) are crucial for insulin dosing decisions.
  • Understanding study design is essential for evaluating CGM accuracy.
  • Not all CGMs are created equal; performance varies significantly.
  • Key questions to assess CGM accuracy include the study population and testing conditions.
  • Robust testing conditions are necessary for reliable sensor performance.
  • The importance of peer-reviewed data in evaluating CGM accuracy.
  • Standardization in CGM technology is on the horizon.
  • Healthcare professionals should be knowledgeable about CGM performance.
  • A downloadable chart will be available to help users assess CGM options.

Chapters

00:00
Introduction to Diabetes Management

02:14
Understanding Continuous Glucose Monitoring (CGM)

05:11
Accuracy of Continuous Glucose Monitors

10:13
Evaluating Sensor Performance

15:45
Key Questions for Sensor Accuracy

20:31
Moving Towards Standardization in CGM

25:03
Summary and Next Steps


Key Resources

CGM Series: Understanding Risk Before Performance

Chart for CGM Devices (From May 2025): DSN Forum

Tim Street @ Diabettech


 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-16952416 Thu, 10 Apr 2025 15:00:00 +0100 1668 full false 9 - ATTD 2025 Highlights and New CGMs (Good, Bad and Ugly!) 9 - ATTD 2025 Highlights and New CGMs (Good, Bad and Ugly!) Suggest guests or get in contact

In this episode of the Glucose Never Lies podcast, John Pemberton shares insights from the ATTD 2025 conference, discussing advancements in diabetes management technologies, including automated insulin delivery systems and continuous glucose monitoring. He emphasizes the importance of early intervention with AID systems, the role of GLP-1 receptor agonists, and the impact of exercise and nutrition on diabetes control. The conversation also highlights the need for equitable access to diabetes technology and the improvements in quality of life that these innovations can bring.

Takeaways

  • Automated insulin delivery systems can improve glycemic control and quality of life.
  • Starting AID systems early can lead to better long-term outcomes.
  • GLP-1 receptor agonists show promise for type 2 diabetes management.
  • Exercise plays a significant role in managing diabetes effectively.
  • Nutrition strategies are essential for optimizing insulin delivery systems.
  • Equity in access to diabetes technology is a pressing issue.
  • Continuous glucose monitoring devices are rapidly evolving.
  • The future of diabetes management looks promising with new technologies.

Chapters

00:00
Introduction to the Podcast and Personal Journey

02:14
Insights from ATTD 2025 Conference

03:41
Advancements in Automated Insulin Delivery Systems

08:22
Exploring GLP-1 Receptor Agonists and Insulin Resistance

10:42
The Role of Exercise in Diabetes Management

14:07
Nutrition and Automated Insulin Delivery Systems

16:03
Quality of Life Improvements with AID Systems

17:55
Equity in Access to Diabetes Technology

19:18
Continuous Glucose Monitoring Innovations

24:05
Future Directions in Diabetes Management 

 

Show Notes & Resources

 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

In this episode of the Glucose Never Lies podcast, John Pemberton shares insights from the ATTD 2025 conference, discussing advancements in diabetes management technologies, including automated insulin delivery systems and continuous glucose monitoring. He emphasizes the importance of early intervention with AID systems, the role of GLP-1 receptor agonists, and the impact of exercise and nutrition on diabetes control. The conversation also highlights the need for equitable access to diabetes technology and the improvements in quality of life that these innovations can bring.

Takeaways

  • Automated insulin delivery systems can improve glycemic control and quality of life.
  • Starting AID systems early can lead to better long-term outcomes.
  • GLP-1 receptor agonists show promise for type 2 diabetes management.
  • Exercise plays a significant role in managing diabetes effectively.
  • Nutrition strategies are essential for optimizing insulin delivery systems.
  • Equity in access to diabetes technology is a pressing issue.
  • Continuous glucose monitoring devices are rapidly evolving.
  • The future of diabetes management looks promising with new technologies.

Chapters

00:00
Introduction to the Podcast and Personal Journey

02:14
Insights from ATTD 2025 Conference

03:41
Advancements in Automated Insulin Delivery Systems

08:22
Exploring GLP-1 Receptor Agonists and Insulin Resistance

10:42
The Role of Exercise in Diabetes Management

14:07
Nutrition and Automated Insulin Delivery Systems

16:03
Quality of Life Improvements with AID Systems

17:55
Equity in Access to Diabetes Technology

19:18
Continuous Glucose Monitoring Innovations

24:05
Future Directions in Diabetes Management 

 

Show Notes & Resources

 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-16880010 Sat, 29 Mar 2025 13:00:00 +0000 1606 full false 8a: 99 Problems (But Highs Ain’t One) — The 20 by 2 Rule 8a: 99 Problems (But Highs Ain’t One) — The 20 by 2 Rule Suggest guests or get in contact

This bonus Episode 8B is a family special — co-created with my daughter Grace. 

It takes the science of activity lowering glucose and flips it into something fun: a rap we call 99 Problems (But Highs Ain’t One).

The key message? 

When you’re above 10 mmol/L (180 mg/dL), just 20 minutes of activity can drop glucose by 2 mmol/L (≈40 mg/dL). That’s the “20 by 2” (or 20 by 40) rule. 

But, Grace said 8 years olds don’t want to hear 20 by 2! They want to hear it in a fun way! So, she made up a rap, with the help of Chad! 

Here is the Chorus:

If you’re having glucose problems, I feel bad for your son,

I’ve got 99 problems but high glucose ain’t one — hit me.

I know Dr Addala will be proud  

If you enjoyed this, explore more:

Want more on the science backing it up?

Listen or Watch:

Find out more at theglucoseneverlies.com

Follow on socials: Twitter/X @GlucoseNLies | Instagram @theglucoseneverlies | LinkedIn John Pemberton

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

This bonus Episode 8B is a family special — co-created with my daughter Grace. 

It takes the science of activity lowering glucose and flips it into something fun: a rap we call 99 Problems (But Highs Ain’t One).

The key message? 

When you’re above 10 mmol/L (180 mg/dL), just 20 minutes of activity can drop glucose by 2 mmol/L (≈40 mg/dL). That’s the “20 by 2” (or 20 by 40) rule. 

But, Grace said 8 years olds don’t want to hear 20 by 2! They want to hear it in a fun way! So, she made up a rap, with the help of Chad! 

Here is the Chorus:

If you’re having glucose problems, I feel bad for your son,

I’ve got 99 problems but high glucose ain’t one — hit me.

I know Dr Addala will be proud  

If you enjoyed this, explore more:

Want more on the science backing it up?

Listen or Watch:

Find out more at theglucoseneverlies.com

Follow on socials: Twitter/X @GlucoseNLies | Instagram @theglucoseneverlies | LinkedIn John Pemberton

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> https://theglucoseneverlies.com/8-activity-snacking-increase-time-range/ John Pemberton Buzzsprout-17798840 Wed, 12 Mar 2025 12:00:00 +0000 83 T1D, CGM, Activty 8 full false 8 - Activity Snacking to Increase Time in Range for T1D 8 - Activity Snacking to Increase Time in Range for T1D Suggest guests or get in contact

Welcome to The Glucose Never Lies® podcast

 In today’s episode, we explore a game-changing approach to glucose control—activity snacking. If you’ve ever struggled with post-meal spikes, found insulin too slow to bring down highs, or wondered how movement could help stabilise your blood glucose, this episode is for you.

I’ll be sharing the latest research on how small, frequent movements can supercharge insulin, improve time in range, and reduce glucose highs without the need for extra insulin corrections. We will discuss practical strategies such as the “3 every 30” method, which involves moving for three minutes every 30 minutes to maintain stable glucose levels. We will also cover the benefits of walking before or after meals to prevent glucose spikes and introduce the “15 by 2” rule, a simple technique to lower high glucose levels faster than waiting for correction doses to take effect.

Stay tuned to the end to hear: 99 Problems, But High Glucose Ain't One

In addition to these strategies, I will break down groundbreaking studies that demonstrate the impact of movement on glucose regulation. Whether you are living with type 1 diabetes, supporting someone who is, or simply looking to optimise your health, this episode is packed with valuable insights that you can put into action immediately.

Click here for more info and the show notes 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Welcome to The Glucose Never Lies® podcast

 In today’s episode, we explore a game-changing approach to glucose control—activity snacking. If you’ve ever struggled with post-meal spikes, found insulin too slow to bring down highs, or wondered how movement could help stabilise your blood glucose, this episode is for you.

I’ll be sharing the latest research on how small, frequent movements can supercharge insulin, improve time in range, and reduce glucose highs without the need for extra insulin corrections. We will discuss practical strategies such as the “3 every 30” method, which involves moving for three minutes every 30 minutes to maintain stable glucose levels. We will also cover the benefits of walking before or after meals to prevent glucose spikes and introduce the “15 by 2” rule, a simple technique to lower high glucose levels faster than waiting for correction doses to take effect.

Stay tuned to the end to hear: 99 Problems, But High Glucose Ain't One

In addition to these strategies, I will break down groundbreaking studies that demonstrate the impact of movement on glucose regulation. Whether you are living with type 1 diabetes, supporting someone who is, or simply looking to optimise your health, this episode is packed with valuable insights that you can put into action immediately.

Click here for more info and the show notes 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-16751777 Fri, 07 Mar 2025 15:00:00 +0000 1659 full false 7 - Fundamentals of The Glucose Never Lies 7 - Fundamentals of The Glucose Never Lies Suggest guests or get in contact

Welcome to The Glucose Never Lies® Podcast!

In this episode, we’re laying down the fundamentals of diabetes management—the essential principles you need to understand to make informed decisions about your health. We’ll break down:

  • What happens when you eat carbohydrates and how your body processes glucose
  • Why insulin behaves differently in type 1 diabetes, leading to post-meal spikes
  •  How physical activity supercharges insulin, making it work more effectively
  • The science behind high-fat meals and why they cause insulin resistance

Whether you're living with diabetes or supporting someone who is, this episode serves as your go-to reference for making sense of the science behind glucose control. Plus, we’ll be sharing actionable strategies to help you optimize your insulin and activity levels for better outcomes.

Click here for more info and the show notes.


Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Welcome to The Glucose Never Lies® Podcast!

In this episode, we’re laying down the fundamentals of diabetes management—the essential principles you need to understand to make informed decisions about your health. We’ll break down:

  • What happens when you eat carbohydrates and how your body processes glucose
  • Why insulin behaves differently in type 1 diabetes, leading to post-meal spikes
  •  How physical activity supercharges insulin, making it work more effectively
  • The science behind high-fat meals and why they cause insulin resistance

Whether you're living with diabetes or supporting someone who is, this episode serves as your go-to reference for making sense of the science behind glucose control. Plus, we’ll be sharing actionable strategies to help you optimize your insulin and activity levels for better outcomes.

Click here for more info and the show notes.


Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-16751545 Fri, 07 Mar 2025 15:00:00 +0000 951 full false 6 - Ten Tips to Optimise Time in Range with AID Systems 6 - Ten Tips to Optimise Time in Range with AID Systems Suggest guests or get in contact

Welcome to The Glucose Neverlies Podcast. 

In this episode, we’re diving into practical strategies to optimise time in range (TIR) when using Automated Insulin Delivery (AID) systems for type 1 diabetes. Managing blood glucose levels can be unpredictable, but AID systems have transformed diabetes care by automating insulin delivery in smarter, more responsive ways. However, achieving the best possible outcomes still requires understanding key strategies, fine-tuning your approach, and making small adjustments that have a big impact.

In this episode, we’ll explore ten essential tips that can help improve your time in range, covering everything from pre-bolus strategies and exercise adjustments to high-fat meal management, CGM optimisation, and insulin site rotation. Whether you’re new to AID or looking to refine your approach, these evidence-based tips will help you navigate everyday challenges and make the most of your system’s capabilities.

We’ll break down the importance of balanced meals combined with post-meal activity, how to adjust insulin for high-fat and protein meals, and ways to prevent post-meal spikes by fine-tuning the timing and location of insulin administration. We’ll also cover exercise adjustments using the 50/50/20 and T25/T25 methods, ensuring you can keep glucose stable before, during, and after physical activity. Plus, we’ll discuss site management for insulin absorption, CGM accuracy tricks, and how to handle alcohol safely with an AID system.

As always, every person’s diabetes management is unique, so these strategies should be discussed with your healthcare team before making any changes. If you’re ready to take your AID experience to the next level, let’s get started.

For more info

Ten Tips to Optimise Time in Range with AID Systems

Show Notes and Transcription

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Welcome to The Glucose Neverlies Podcast. 

In this episode, we’re diving into practical strategies to optimise time in range (TIR) when using Automated Insulin Delivery (AID) systems for type 1 diabetes. Managing blood glucose levels can be unpredictable, but AID systems have transformed diabetes care by automating insulin delivery in smarter, more responsive ways. However, achieving the best possible outcomes still requires understanding key strategies, fine-tuning your approach, and making small adjustments that have a big impact.

In this episode, we’ll explore ten essential tips that can help improve your time in range, covering everything from pre-bolus strategies and exercise adjustments to high-fat meal management, CGM optimisation, and insulin site rotation. Whether you’re new to AID or looking to refine your approach, these evidence-based tips will help you navigate everyday challenges and make the most of your system’s capabilities.

We’ll break down the importance of balanced meals combined with post-meal activity, how to adjust insulin for high-fat and protein meals, and ways to prevent post-meal spikes by fine-tuning the timing and location of insulin administration. We’ll also cover exercise adjustments using the 50/50/20 and T25/T25 methods, ensuring you can keep glucose stable before, during, and after physical activity. Plus, we’ll discuss site management for insulin absorption, CGM accuracy tricks, and how to handle alcohol safely with an AID system.

As always, every person’s diabetes management is unique, so these strategies should be discussed with your healthcare team before making any changes. If you’re ready to take your AID experience to the next level, let’s get started.

For more info

Ten Tips to Optimise Time in Range with AID Systems

Show Notes and Transcription

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-16743225 Thu, 06 Mar 2025 03:00:00 +0000 2296 full false 5 - Mastering Omnipod 5 – The Iron Man of AID Systems 5 - Mastering Omnipod 5 – The Iron Man of AID Systems Suggest guests or get in contact

Welcome to The Glucose Neverlies Podcast. 

In this episode, we’re focusing on Omnipod 5, the sleek, high-tech Automated Insulin Delivery (AID) system that offers simplicity, automation, and a tubeless design. Much like Iron Man’s suit, Omnipod 5 is built for efficiency and ease, allowing for seamless insulin adjustments without the hassle of tubing. If you’re looking for a system that requires minimal user input and delivers smart automation, this could be the perfect choice for you.

Omnipod 5 uses SmartAdjust technology, an adaptive algorithm housed inside the pod itself, which adjusts insulin every five minutes to help maintain stable glucose levels. The system learns from previous insulin needs and automatically fine-tunes basal rates, making it incredibly easy to use. However, as with any powerful technology, understanding how the system works, how to optimise settings, and how to manage common challenges will help you get the best results.

In this episode, we’ll break down the SmartAdjust algorithm, discuss key starting settings, and share tips and tricks to help you maximise your time in range. We’ll also cover how to prevent and treat hypos, navigate high-fat meals like pizza, and adjust for exercise, whether you prefer a quick approach or a more structured plan.

With Omnipod 5, the first step is to survive, and then thrive. Whether you’re new to the system or fine-tuning your experience, this episode will guide you through everything you need to know to get the most out of Omnipod 5 and take your diabetes management to the next level. Let’s get started.

For more info

Mastering Omnipod 5 – The Iron Man of AID Systems

Show Notes and Transcription

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Welcome to The Glucose Neverlies Podcast. 

In this episode, we’re focusing on Omnipod 5, the sleek, high-tech Automated Insulin Delivery (AID) system that offers simplicity, automation, and a tubeless design. Much like Iron Man’s suit, Omnipod 5 is built for efficiency and ease, allowing for seamless insulin adjustments without the hassle of tubing. If you’re looking for a system that requires minimal user input and delivers smart automation, this could be the perfect choice for you.

Omnipod 5 uses SmartAdjust technology, an adaptive algorithm housed inside the pod itself, which adjusts insulin every five minutes to help maintain stable glucose levels. The system learns from previous insulin needs and automatically fine-tunes basal rates, making it incredibly easy to use. However, as with any powerful technology, understanding how the system works, how to optimise settings, and how to manage common challenges will help you get the best results.

In this episode, we’ll break down the SmartAdjust algorithm, discuss key starting settings, and share tips and tricks to help you maximise your time in range. We’ll also cover how to prevent and treat hypos, navigate high-fat meals like pizza, and adjust for exercise, whether you prefer a quick approach or a more structured plan.

With Omnipod 5, the first step is to survive, and then thrive. Whether you’re new to the system or fine-tuning your experience, this episode will guide you through everything you need to know to get the most out of Omnipod 5 and take your diabetes management to the next level. Let’s get started.

For more info

Mastering Omnipod 5 – The Iron Man of AID Systems

Show Notes and Transcription

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-16743108 Thu, 06 Mar 2025 03:00:00 +0000 936 full false 4 - Mastering CamAPS FX – The Batman of AID Systems 4 - Mastering CamAPS FX – The Batman of AID Systems Suggest guests or get in contact

Welcome to The Glucose Neverlies Podcast. 

In this episode, we are exploring CamAPS FX, an Automated Insulin Delivery (AID) system that, much like Batman, relies on strategy, adaptability, and precise control to outsmart unpredictable glucose levels. If you’re looking for a system that allows multiple glucose targets throughout the day, advanced algorithm learning, and the ability to fine-tune your insulin delivery, then CamAPS FX might be your perfect match.

Designed for those who need tight glucose control, such as during pregnancy or when managing fluctuating insulin sensitivity, CamAPS FX is the most flexible and well-researched AID system available across all age groups. Its continuously adapting algorithm learns from your insulin needs, making it one of the most advanced tools for diabetes management. However, like all great technology, getting the best results requires understanding how the system works and applying key strategies.

In this episode, we will break down how the CamAPS FX algorithm functions, the key starting settings, and the essential tips and tricks that will help you maximise time in range. We will also explore how to prevent and manage hypos, optimise insulin delivery for high-fat meals, and adjust settings for exercise using both quick and comprehensive approaches.

With CamAPS FX, the first step is to survive, and then thrive. Whether you're new to the system or looking to fine-tune your approach, this episode will guide you through everything you need to know to master CamAPS FX and take full control of your diabetes management. Let’s get started.

For more info:

Mastering CamAPS FX – The Batman of AID Systems

Show Notes and Transcription

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Welcome to The Glucose Neverlies Podcast. 

In this episode, we are exploring CamAPS FX, an Automated Insulin Delivery (AID) system that, much like Batman, relies on strategy, adaptability, and precise control to outsmart unpredictable glucose levels. If you’re looking for a system that allows multiple glucose targets throughout the day, advanced algorithm learning, and the ability to fine-tune your insulin delivery, then CamAPS FX might be your perfect match.

Designed for those who need tight glucose control, such as during pregnancy or when managing fluctuating insulin sensitivity, CamAPS FX is the most flexible and well-researched AID system available across all age groups. Its continuously adapting algorithm learns from your insulin needs, making it one of the most advanced tools for diabetes management. However, like all great technology, getting the best results requires understanding how the system works and applying key strategies.

In this episode, we will break down how the CamAPS FX algorithm functions, the key starting settings, and the essential tips and tricks that will help you maximise time in range. We will also explore how to prevent and manage hypos, optimise insulin delivery for high-fat meals, and adjust settings for exercise using both quick and comprehensive approaches.

With CamAPS FX, the first step is to survive, and then thrive. Whether you're new to the system or looking to fine-tune your approach, this episode will guide you through everything you need to know to master CamAPS FX and take full control of your diabetes management. Let’s get started.

For more info:

Mastering CamAPS FX – The Batman of AID Systems

Show Notes and Transcription

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-16743003 Thu, 06 Mar 2025 03:00:00 +0000 862 full false 3 - Mastering the Medtronic 780G – The Incredible Hulk of AID Systems 3 - Mastering the Medtronic 780G – The Incredible Hulk of AID Systems Suggest guests or get in contact

Welcome to The Glucose Neverlies Podcast. 

In this episode, we’re taking a deep dive into the Medtronic 780G, a powerful Automated Insulin Delivery (AID) system designed to crush after-meal highs and optimise time in range. Just like the Hulk, the 780G is strong, aggressive, and highly automated, making it one of the most proactive systems available. If you’re considering the 780G or already using it, we’ll walk you through everything you need to know to make the most of this powerhouse system.

With its ability to automatically correct high glucose levels every five minutes, the 780G requires minimal user intervention. It features strong overnight glucose control and allows for customisable target settings. However, like any powerful tool, understanding how the SmartGuard algorithm works is key to getting the best results. In this episode, we’ll cover how the algorithm functions, how to optimise your starting settings, and practical tips and tricks to ensure smooth and effective use.

We’ll also explore strategies for preventing and treating hypos, as well as managing high-fat meals like pizza and takeaways, where SmartGuard may need a little extra help. Exercise is another important consideration, and we’ll discuss both quick adjustments and comprehensive planning methods to keep your glucose levels stable during physical activity.

Starting on an AID system can feel overwhelming, but we break it down into two simple phases: First, survive. Then, thrive. Whether you’re new to the 780G or looking to fine-tune your approach, this episode will help you harness its full potential. If you’re ready to unleash the power of the Medtronic 780G and take your diabetes management to the next level, let’s get started.

For more info:

Mastering the Medtronic 780G – The Incredible Hulk of AID Systems

Show Notes and Transcription

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Welcome to The Glucose Neverlies Podcast. 

In this episode, we’re taking a deep dive into the Medtronic 780G, a powerful Automated Insulin Delivery (AID) system designed to crush after-meal highs and optimise time in range. Just like the Hulk, the 780G is strong, aggressive, and highly automated, making it one of the most proactive systems available. If you’re considering the 780G or already using it, we’ll walk you through everything you need to know to make the most of this powerhouse system.

With its ability to automatically correct high glucose levels every five minutes, the 780G requires minimal user intervention. It features strong overnight glucose control and allows for customisable target settings. However, like any powerful tool, understanding how the SmartGuard algorithm works is key to getting the best results. In this episode, we’ll cover how the algorithm functions, how to optimise your starting settings, and practical tips and tricks to ensure smooth and effective use.

We’ll also explore strategies for preventing and treating hypos, as well as managing high-fat meals like pizza and takeaways, where SmartGuard may need a little extra help. Exercise is another important consideration, and we’ll discuss both quick adjustments and comprehensive planning methods to keep your glucose levels stable during physical activity.

Starting on an AID system can feel overwhelming, but we break it down into two simple phases: First, survive. Then, thrive. Whether you’re new to the 780G or looking to fine-tune your approach, this episode will help you harness its full potential. If you’re ready to unleash the power of the Medtronic 780G and take your diabetes management to the next level, let’s get started.

For more info:

Mastering the Medtronic 780G – The Incredible Hulk of AID Systems

Show Notes and Transcription

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-16742948 Thu, 06 Mar 2025 03:00:00 +0000 720 full false 2 - Mastering Control-IQ – The Spider-Man of AID Systems 2 - Mastering Control-IQ – The Spider-Man of AID Systems Suggest guests or get in contact

Welcome to The Glucose Neverlies Podcast

In today’s episode, we are exploring the Tandem t:slim X2 with Control-IQ, a system that offers great power but also requires great responsibility. If you are considering this system or already using it, this episode will guide you through everything you need to know to make the most of Control-IQ.

With its highly customisable algorithm, multiple insulin profiles, and Activity and Sleep modes, Control-IQ provides a high degree of flexibility. However, much like Spider-Man’s abilities, this power requires understanding and maintenance. We will cover how the algorithm works, the key settings you need to get started, and essential tips and tricks to help you maximise your time in range. We will also discuss strategies for preventing and treating hypoglycaemia, managing high-fat meals, and adjusting for exercise to ensure you stay in control.

Control-IQ is built on three main components: the t:slim X2 pump, Dexcom G6/G7 or Libre 2 Plus (depending on where you live), and the onboard Control-IQ algorithm. Understanding how these elements interact is crucial for optimising the system. The algorithm adjusts insulin delivery based on manually set basal rates and correction factors, which provides both automation and control. However, achieving the best results requires effort, particularly in fine-tuning the correction factor, which is key to determining how aggressively the algorithm responds to high glucose levels.

We will also explore common challenges, including how to handle high-fat meals such as pizza, how to adjust for exercise, and how to prevent hypos before they happen. Whether you prefer a quick and simple approach or a more structured plan, we will guide you through how to manage Control-IQ effectively.

If you are ready to take control like Spider-Man, let’s get started.

For more information:

Mastering t:slim with Control IQ - The Spider-Man of AID Systems

Show Notes and Transcription

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Welcome to The Glucose Neverlies Podcast

In today’s episode, we are exploring the Tandem t:slim X2 with Control-IQ, a system that offers great power but also requires great responsibility. If you are considering this system or already using it, this episode will guide you through everything you need to know to make the most of Control-IQ.

With its highly customisable algorithm, multiple insulin profiles, and Activity and Sleep modes, Control-IQ provides a high degree of flexibility. However, much like Spider-Man’s abilities, this power requires understanding and maintenance. We will cover how the algorithm works, the key settings you need to get started, and essential tips and tricks to help you maximise your time in range. We will also discuss strategies for preventing and treating hypoglycaemia, managing high-fat meals, and adjusting for exercise to ensure you stay in control.

Control-IQ is built on three main components: the t:slim X2 pump, Dexcom G6/G7 or Libre 2 Plus (depending on where you live), and the onboard Control-IQ algorithm. Understanding how these elements interact is crucial for optimising the system. The algorithm adjusts insulin delivery based on manually set basal rates and correction factors, which provides both automation and control. However, achieving the best results requires effort, particularly in fine-tuning the correction factor, which is key to determining how aggressively the algorithm responds to high glucose levels.

We will also explore common challenges, including how to handle high-fat meals such as pizza, how to adjust for exercise, and how to prevent hypos before they happen. Whether you prefer a quick and simple approach or a more structured plan, we will guide you through how to manage Control-IQ effectively.

If you are ready to take control like Spider-Man, let’s get started.

For more information:

Mastering t:slim with Control IQ - The Spider-Man of AID Systems

Show Notes and Transcription

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-16742806 Thu, 06 Mar 2025 03:00:00 +0000 1002 full false 1 - Choosing an AID System: Which Superhero Do You Want in Your Corner? 1 - Choosing an AID System: Which Superhero Do You Want in Your Corner? Suggest guests or get in contact

Welcome to The Glucose Neverlies Podcast!

When it comes to Automated Insulin Delivery (AID) systems, there is no single "best" option, only the right one for each individual. Choosing an AID system can feel overwhelming, but with the help of my good friend, colleague, and Diabetes Nurse Extraordinaire, Louise Collins, we have transformed the decision into something much more fun: selecting a superhero.

Each AID system has its own strengths, weaknesses, and unique characteristics, making them better suited to different people and situations. Some prefer control and flexibility, like Spider-Man, while others want the sheer power and aggressive glucose correction of the Hulk. Those who favour strategic adaptability might relate more to Batman, while others may prefer the sleek, automated ease of Iron Man.

In this episode, we compare the four leading AID systems—Tandem t:slim X2, Medtronic 780G, CamAPS FX, and Omnipod 5—through the lens of the superheroes they most resemble. By the end, you’ll have a clearer idea of which system might suit your lifestyle and diabetes management style best.

Whether you value customisation, automation, or a balance of both, the key to success with any AID system is choosing the one that works best for you. Let’s dive in! 

For the detials

The Superhero guide

The Deep Dive Guide

CGM Systems Guide

Show Notes and Transcriptions

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

Welcome to The Glucose Neverlies Podcast!

When it comes to Automated Insulin Delivery (AID) systems, there is no single "best" option, only the right one for each individual. Choosing an AID system can feel overwhelming, but with the help of my good friend, colleague, and Diabetes Nurse Extraordinaire, Louise Collins, we have transformed the decision into something much more fun: selecting a superhero.

Each AID system has its own strengths, weaknesses, and unique characteristics, making them better suited to different people and situations. Some prefer control and flexibility, like Spider-Man, while others want the sheer power and aggressive glucose correction of the Hulk. Those who favour strategic adaptability might relate more to Batman, while others may prefer the sleek, automated ease of Iron Man.

In this episode, we compare the four leading AID systems—Tandem t:slim X2, Medtronic 780G, CamAPS FX, and Omnipod 5—through the lens of the superheroes they most resemble. By the end, you’ll have a clearer idea of which system might suit your lifestyle and diabetes management style best.

Whether you value customisation, automation, or a balance of both, the key to success with any AID system is choosing the one that works best for you. Let’s dive in! 

For the detials

The Superhero guide

The Deep Dive Guide

CGM Systems Guide

Show Notes and Transcriptions

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-16742748 Thu, 06 Mar 2025 03:00:00 +0000 1810 full false 0 — Welcome to The Glucose Never Lies® Podcast 0 — Welcome to The Glucose Never Lies® Podcast Suggest guests or get in contact

What this podcast is all about

I’m John Pemberton — diabetes educator, researcher, and proud dad living with type 1 diabetes. The Glucose Never Lies® Podcast is where science, lived experience, and curiosity collide.

This series is for:

  • People with type 1 diabetes who want practical, evidence-based tools they can use every day.
  • Healthcare professionals looking for clear explanations and insights from the latest research.
  • Anyone curious about the future of diabetes care, technology, and self-management.

Each episode we’ll bring together top researchers, clinicians, and people living with diabetes to explore the big questions — from CGM accuracy and exercise strategies, to emerging therapies and the lived experience of diabetes.

Why “The Glucose Never Lies®”?

Because glucose is the ultimate feedback signal. It tells us what’s happening in real time, whether we like it or not. Understanding and acting on that truth is how we move forward — in our health, and in diabetes science.

Support the podcast

This project is built on passion, not profit. If you enjoy it and want to help me keep it going:

🎧 Options

Feedback always welcome, the good, the bad, and the ugly: john@theglucoseneverlies.com 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> Suggest guests or get in contact

What this podcast is all about

I’m John Pemberton — diabetes educator, researcher, and proud dad living with type 1 diabetes. The Glucose Never Lies® Podcast is where science, lived experience, and curiosity collide.

This series is for:

  • People with type 1 diabetes who want practical, evidence-based tools they can use every day.
  • Healthcare professionals looking for clear explanations and insights from the latest research.
  • Anyone curious about the future of diabetes care, technology, and self-management.

Each episode we’ll bring together top researchers, clinicians, and people living with diabetes to explore the big questions — from CGM accuracy and exercise strategies, to emerging therapies and the lived experience of diabetes.

Why “The Glucose Never Lies®”?

Because glucose is the ultimate feedback signal. It tells us what’s happening in real time, whether we like it or not. Understanding and acting on that truth is how we move forward — in our health, and in diabetes science.

Support the podcast

This project is built on passion, not profit. If you enjoy it and want to help me keep it going:

🎧 Options

Feedback always welcome, the good, the bad, and the ugly: john@theglucoseneverlies.com 

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://buymeacoffee.com/gnlfree

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.

]]> John Pemberton Buzzsprout-16661341 Thu, 20 Feb 2025 06:00:00 +0000 97 1 trailer false